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A B S T R A C T
Background
Colorectal cancer including rectal cancer is the third most common cause of cancer deaths in the western world. For colon carcinoma,
laparoscopic surgery is proven to result in faster postoperative recovery, fewer complications and better cosmetic results with equal
oncologic results. These short-term benefits are expected to be similar for laparoscopic rectal cancer surgery. However, the oncological
safety of laparoscopic surgery for rectal cancer remained controversial due to the lack of definitive long-term results. Thus, the expected
short-term benefits can only be of interest when oncological results are at least equal.
Objectives
To evaluate the differences in short- and long-term results after elective laparoscopic total mesorectal excision (LTME) for the resection
of rectal cancer compared with open total mesorectal excision (OTME).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2013, Issue 2), MEDLINE
(January 1990 to February 2013), EMBASE (January 1990 to February 2013), ClinicalTrials.gov (February 2013) and Current
Controlled Trials (February 2013). We handsearched the reference lists of the included articles for missed studies.
Selection criteria
Only randomised controlled trials (RCTs) comparing LTMEandOTME, reporting at least one of our outcomemeasures, was considered
for inclusion.
Data collection and analysis
Two authors independently assessed study quality according to the CONSORT statement, and resolved disagreements by discussion.
We rated the quality of the evidence using GRADE methods.
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Main results
We identified 45 references out of 953 search results, of which 14 studies met the inclusion criteria involving 3528 rectal cancer patients.
We did not consider the risk of bias of the included studies to have impacted on the quality of the evidence. Data were analysed
according to an intention-to-treat principle with a mean conversion rate of 14.5% (range 0% to 35%) in the laparoscopic group.
There was moderate quality evidence that laparoscopic and open TME had similar effects on five-year disease-free survival (OR 1.02;
95% CI 0.76 to1.38, 4 studies, N = 943). The estimated effects of laparoscopic and open TME on local recurrence and overall survival
were similar, although confidence intervals were wide, both with moderate quality evidence (local recurrence: OR 0.89; 95% CI 0.57
to1.39 and overall survival rate: OR 1.15; 95% CI 0.87 to1.52). There was moderate to high quality evidence that the number of
resected lymph nodes and surgical margins were similar between the two groups.
For the short-term results, length of hospital stay was reduced by two days (95% CI -3.22 to -1.10), moderate quality evidence), and
the time to first defecation was shorter in the LTME group (-0.86 days; 95% CI -1.17 to -0.54). There was moderate quality evidence
that 30 days morbidity were similar in both groups (OR 0.94; 95% CI 0.8 to 1.1). There were fewer wound infections (OR 0.68; 95%
CI 0.50 to 0.93) and fewer bleeding complications (OR 0.30; 95% CI 0.10 to 0.93) in the LTME group.
There was no clear evidence of any differences in quality of life after LTME or OTME regarding functional recovery, bladder and sexual
function. The costs were higher for LTME with differences up to GBP 2000 for direct costs only.
Authors’ conclusions
We have found moderate quality evidence that laparoscopic total mesorectal excision (TME) has similar effects to open TME on long
term survival outcomes for the treatment of rectal cancer. The quality of the evidence was downgraded due to imprecision and further
research could impact on our confidence in this result. There is moderate quality evidence that it leads to better short-term post-surgical
outcomes in terms of recovery for non-locally advanced rectal cancer. Currently results are consistent in showing a similar disease-free
survival and overall survival, and for recurrences after at least three years and up to 10 years, although due to imprecision we cannot rule
out superiority of either approach. We await long-term data from a number of ongoing and recently completed studies to contribute
to a more robust analysis of long-term disease free, overall survival and local recurrence.
P L A I N L A N G U A G E S U M M A R Y
Keyhole laparoscopic or open surgery for rectal cancer
Colorectal (large bowel) cancer including rectal cancer is the third most common cause of cancer deaths in the western world. The
risk of developing rectal cancer increases with age and is most common in people around 70 years of age. The treatment consists of
complete surgical resection of the tumour and surrounding tissue by a technique called total mesorectal excision (TME), sometimes
combined with chemotherapy and radiotherapy. This surgery can be performed by either normal open abdominal surgery with a large
incision or by keyhole laparoscopic surgery with several small incisions for the instruments and camera. For colon cancer, laparoscopic
surgery is proven to result in faster postoperative recovery, fewer complications and better cosmetic results. These results are expected
to be equal for rectal surgery. However, surgery for rectal cancer is technically more difficult than for colon cancer due to the location
deeper in the pelvis and close to important nerves. Therefore a complete and safe resection of the tumour should be guaranteed, this is
important to reduce the risk of recurrence of the tumour and could be tested by assessing recurrence rates and patient survival in the
long term.
In this updated review, we have assessed all randomised studies of laparoscopic and open TME for rectal cancer, to compare and combine
their results. We included 14 trials reporting on a total of 3528 patients undergoing rectal cancer surgery. In 14.5% of those having
laparoscopic surgery needed conversion to open surgery by a large incision in the abdomen due to difficulties or problems during the
procedure.
There is currently moderate quality evidence that laparoscopic total mesorectal excision (LTME) has similar effects to open TME
(OTME) on long term survival outcomes for the treatment of rectal cancer. The estimated effect was imprecise and further research
could impact on our confidence int this result. There is moderate quality evidence that it leads to better short-term post-surgical
outcomes in terms of length of hospital stay. We found that pain was lower in the LTME group and that resumption of diet was better.
We did not find clear evidence of a difference in quality of life between the two groups, but costs were higher for LTME. We await
long-term data from a number of ongoing and recently completed studies to contribute to our understanding of the effects of these
surgical approaches on long-term disease free, overall survival and local recurrence.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Laparoscopic versus open total mesorectal excision (TM E) for rectal cancer
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Lymph nodes retrieved The mean number of lymph
nodes retrieved in the inter-
vent ion groups was
0.43 lower





























































































































Hospital stay (days) The mean length of hospi-
tal stay in the intervent ion
groups was
2.16 days shorter





* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Stat ist ical inaccuracy with wide conf idence interval at both sides
2Stat ist ical inaccuracy with wide conf idence interval at both sides, but a tendency for a higher overall survival for LTME
3Stat ist ical inaccuracy with wide conf idence interval at both sides, but a tendency for a lower recurrence rate for LTME
4Only 8 studies provided data on CRM posit ivity
5Def init ion of overall morbidity varied or was unclear









































































































B A C K G R O U N D
Description of the condition
The incidence of rectal cancer in the western world is 28% to 35%
of the total colorectal cancer incidence, with 15 to 25/100,000
new patients per year for both men and women. The risk increases
with age, with a median age of 70 years at the time of diagnosis;
the associated mortality is between 4 and 10 per 100,000 per year
(Glimelius 2013). Symptoms suggesting rectal cancer typically in-
clude changes in bowel habits, the feeling of incomplete empty-
ing, rectal bleeding, anaemia or weight loss. The diagnosis can be
made by tumour biopsy during colonoscopy or sigmoidoscopy. If
rectal cancer is confirmed, the extent of the disease is examined by
imaging of the chest and liver for signs of metastases, andmagnetic
resonance imaging (MRI) of the pelvis and/or endorectal ultra-
sound (ERUS) are done to determine the degree of rectal wall and
mesorectal fascia invasion. The majority of rectal carcinomas are
adenocarcinoma (95% to 98%), usually arising from an adenoma
(Glimelius 2013; Monson 2013).
Description of the intervention
Complete resection of rectal cancer can be achieved by a sphinc-
ter-preserving anterior resection (AR, rectosigmoid resection) or
an abdominoperineal resection (APR). Both had high local recur-
rence rates until the introduction of the total mesorectal excision
(TME) (Heald 1986). Total mesorectal excision achieves a com-
plete removal of the rectum together with its draining lymphatics,
and results in low rates of recurrence. Despite the successful intro-
duction of laparoscopic and laparoscopic-assisted procedures for
the resection of colonic cancer, surgeons have been more reluctant
to introduce laparoscopic TME due to the technically demanding
resection plane.
How the intervention might work
Laparoscopic and laparoscopic-assisted TME offers several theo-
retical advantages compared to open resection. Itmay be associated
with less blood loss, faster recovery, early feeding and a lower mor-
bidity rate, as shown in laparoscopic colonic surgery (Braga 2002;
Pikarsky 2002). The magnified view of the pelvis afforded by the
laparoscope may facilitate identification of the autonomic nerves
and thus prevent unintentional injury of these nerves. However,
these advantages of LTME are only beneficial to people with rectal
cancer when local recurrence and disease-free survival rates are at
least similar to those achieved with OTME.
Why it is important to do this review
The introduction of laparoscopy 20 years ago has caused major
changes in colorectal surgery. For benign disease, such as diverti-
culitis and inflammatory bowel disease, laparoscopy has become
the surgical technique of choice for its benefits in recovery, compli-
cation rate and cosmetic results. Only recently, sufficient evidence
has become available showing laparoscopic surgery is safe for the
treatment of colonic cancer. Four large randomised trials (472 to
1076 participants) could not show any differences in quality of
resection and long-term recurrence and survival rates between la-
paroscopic and open surgery for colon cancer (MRC CLASICC a
2005; COST2007; COLOR2009; LAPKONII 2009). Although
COLOR 2009 was not able to rule out any difference with their
non-inferiority design, the meta-analysis by Kuhry 2008 did not
show any differences.
Despite the larger number of randomised trials on laparoscopic
surgery for colon cancer, there is still limited evidence for long- and
short-term outcomes after LTME due to the lack of high quality
randomised controlled trials with sufficient follow up. Now the
results of more well designed large randomised controlled trials
(RCTs) become available, there is a need for a updated systematic
review of these results.
O B J E C T I V E S
To evaluate the differences in short- and long-term results after
elective laparoscopic total mesorectal excision (LTME) for the re-
section of rectal cancer compared with open total mesorectal ex-
cision (OTME).
M E T H O D S
Criteria for considering studies for this review
Types of studies
In contrast to the published protocol and previous version of this
review, for this update we have only considered RCTs comparing
LTME to OTME, since sufficient RCTs have become available
since the publication of the original review. We did not apply any
language restrictions.
Types of participants
People with rectal cancer undergoing total mesorectal excision
were considered for inclusion. Studies including participants with
colorectal cancer are only eligible if the results for those with rectal
carcinoma were presented separately.
5Laparoscopic versus open total mesorectal excision for rectal cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of interventions
These include laparoscopic, laparoscopic-assisted or open total
mesorectal excision as (low) anterior resection or abdominoper-
ineal resection. When a primary anastomosis was constructed, it
could either be performed intraperitoneally (’double-stapled’ col-
orectal anastomosis) or extraperitoneally (hand-sewn or stapled
colorectal anastomosis).
Types of outcome measures
We sought the following outcomes in all included studies:
Primary outcomes
- Disease-free and overall survival
Secondary outcomes
- Recurrences (local, wound/port site and distant)
- Quality of resection (circumferential margin (CRM) positivity
and number of lymph nodes)
- Surgical data (surgical time, incision length, conversion rate)
- Intraoperative complications, blood loss and transfusion require-
ment
- Postoperative morbidity and mortality (overall morbidity, need
for reoperation, anastomotic leakage, wound infection, urinary
complications, bleeding, chest infection)
- Postoperative pain (use of medication and visual analogue scale
(VAS) score)
- Gastrointestinal recovery and hospital stay (time to first bowel
movement, time to normal diet, length of hospital stay)
- Long-termmorbidity (incisional herniae and bowel obstruction)
- Quality of life (functional recovery, bladder and sexual function)
- Immunologic response
- Costs
Search methods for identification of studies
Electronic searches
We followed the recommendations of the Cochrane Colorectal
Cancer Group and searched the following bibliographic databases
with no language restrictions in order to identify relevant primary
studies:
CochraneCentral Register ofControlledTrials (CENTRAL) (Jan-
uary 1990 to February 2013);
MEDLINE (January 1990 to February 2013);
EMBASE (January 1990 to February 2013).
We conducted searches using medical subject headings (MeSH)
and free-text words. The search has been adapted for each database
search and is shown in Appendix 1 (CENTRAL), Appendix 2
(MEDLINE) and Appendix 3 (EMBASE).
Searching other resources
We handsearched the reference lists of all selected articles for fur-
ther relevant studies. There was no language restriction. In addi-
tion, we searched for ongoing trials in the ClinicalTrials.gov and
the Current Controlled Trials databases.
Data collection and analysis
Selection of studies
Two authors (SV and LP) independently reviewed all abstracts.
We retrieved full-text copies of all studies that potentially met the
inclusion criteria based on abstract review. If both authors agreed
that a study did not meet the eligibility criteria, we excluded it. If
we disagreed, we resolved conflicts by discussion and consensus or
by consulting a third member of the review team.
Data extraction and management
We collected data according to the outcomes mentioned above.
Each author extracted the data independently from each study and
compared them, resolving disagreement by discussion. We used
Review Manager 5 (RevMan 5.2) software for statistical analysis,
provided by the Cochrane Collaboration. Data not suitable for
meta-analysis is discussed in the results section.
Assessment of risk of bias in included studies
Two authors (SV and LP) have assessed all the selected studies for
methodological quality according to the CONSORT Statement
2010, and have summarised the information in the ’Risk of bias’
figure (Figure 2). In addition, we have used the Cochrane ’Risk
of bias’ tool as described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Measures of treatment effect
Wemeasured the treatment effect using themean difference (MD)
or standardised mean difference (SMD) for continuous data and
the odds ratio (OR) for dichotomous data. Standardised mean
differences were only used when the reported units or drugs varied
between the studies, for instance the number of doses of analgesia.
All outcomes included 95% confidence intervals (CI).
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Unit of analysis issues
For randomised controlled trials for this surgical intervention, we
would expect only a simple parallel design. The only possible cross-
over would be the conversion of laparoscopy to open surgery. Be-
cause worse outcomes for this group can be expected and should
be evaluated as a complication of laparoscopic-intended surgery,
all analyses should be performed on the intention-to-treat princi-
ple.
Dealing with missing data
To avoid missing unpublished studies, we searched clinical trial
databases as stated above. We compared reported outcomes to
published protocols or to the Methods section of each article. If
we found inconsistencies, this is reported in the ’Selective report-
ing’ section of the ’Risk of bias’ table. As missing postoperative
and follow-up data are common in surgical studies, we assume a
random pattern of missingness.
Assessment of heterogeneity
We used the Cochrane Chi² test (Q-test) to assess heterogeneity
and the I² statistic to estimate the degree of heterogeneity (Higgins
2003). We considered an I² of between 0% and 40% as probably
not important, between 30% and 60% as representing moderate
heterogeneity, between 50% and 90% as substantial heterogene-
ity, and between 75% and 100% as considerable heterogeneity
(Higgins 2011). We used a fixed-effect analysis for outcomes with
low heterogeneity.
Assessment of reporting biases
We present an overview of all outcomes per study in the table
Selective reporting (reporting bias).
Data synthesis
We analysed continuous variables using mean differences with
95%confidence intervals. For dichotomous variableswe used odds
ratios with 95% confidence intervals. We constructed forest plots,
using the Mantel-Haenszel method (fixed- or random-effects) to
combine the outcomes. In case of continuous data presented as
median and range, we estimated the mean and standard deviation
according to the methods described by Hozo 2005. We generated
funnel plots to screen for publication bias. In case of inclusion
of an original RCT and the additional publication of a subgroup
of participants, we included only the most appropriate subgroup
data in the meta-analyses, to avoid duplication of data.
Subgroup analysis and investigation of heterogeneity
We had planned subgroup analyses for abdominoperineal resec-
tion (APR) and anterior resection (AR), and for studies allowing
and excluding neoadjuvant therapy. These analyses were not per-
formed because too few studies presented separate data for these
groups. However, we plan to explore these subgroups if possible
in future updates.
Summary of Findings table
We applied methods developed by the GRADE working group to
rate the quality of evidence from RCTs, starting at high quality
and downgrading for risk of bias, imprecision, inconsistency, in-
directness and publication bias.
We rated the quality of the evidence for the following main out-
comes:
1. Disease-free survival at 5 years
2. Overall survival at 5 years
3. Local recurrences
4. Lymph nodes retrieved
5. CRM positivity
6. 30-day morbidity
7. Hospital stay (days)
R E S U L T S
Description of studies
See:Characteristics of included studies, Characteristics of excluded
studies and Characteristics of ongoing studies.
Results of the search
Our searches of theCochraneCentral Register of ControlledTrials
(CENTRAL), MEDLINE and EMBASE identified 90, 253 and
852 results respectively. In addition we handsearched MEDLINE
for any missed publications for the included trials. After exclusion
of duplicates, we screened 953 references and identified 45 eligible
references, as shown in the flow chart (Figure 1).
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Figure 1. Study selection flow diagram.
Included studies
From the 29 references, we identified two ongoing trials and 14
published clinical trials. Most larger trials have published their
results at several stages in different papers. Both ongoing trials
(ACTRN12609000663257 and NCT00726622) are still recruit-
ing participants and no results have been published yet. Of the 14
published trials, two (Kang 2010; COLOR 2 a 2013) completed
participant recruitment but have not yet published long-term data
on survival. The COLOR2 trial has a second published paper on a
local subgroup, referred to as COLOR2 b 2011 in this review. The
Hong Kong trials are divided into the low rectal cancer group in
Ng 2008 and the rectosigmoid group in Hong Kong a 2004, with
the last subdivided in four papers because results are published for
different subgroups as shown in the Characteristics of included
studies. Hong Kong a 2004 is the biggest group, presenting upper
rectum and sigmoid data, Hong Kong b 2009 is the upper rectal
subgroup and reports 10-year follow-up data. Hong Kong c 2000
and Hong Kong d 2003 are both small subgroups of Hong Kong
a 2004 and present only short-term data on immunological re-
sponse.
The UK MRC CLASICC study is presented across nine papers,
with six grouped as MRC CLASICC a 2005, giving respectively
the short-term, three-year, five-year and 10-year results, the costs
and an analysis of long term complications of the same partici-
pant group. MRC CLASICC c 2001 (one) and MRC CLASICC
b 2005 (two) include papers for a selected or local participant sub-
group and are therefore reported separately. King 2006 also con-
sists of two papers, with the second paper focusing on functional
recovery in the same participant group. The remaining eight clin-
ical trials have one reference each, with the note that Zhou 2004
and Zhou 2007 are different trials and different authors despite
the coincidence of names.
All 14 clinical trials were published as full papers and involved
a total of 3528 rectal cancer patients (range 19 to 1044). The
characteristics of these trials are described in 20 separate data sets
and thus tables to allow for sufficient details on six additional
subgroup papers.
All studies had quite similar exclusion criteria. The most com-
mon were: T4 rectal cancer, rectal cancer recurrence, people with
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synchronous or metachronous colorectal cancer, metastatic dis-
ease, emergency surgery, intestinal obstructionor perforation, con-
traindication for laparoscopy and no informed consent. The ma-
jority of the studies described the technique for laparoscopic to-
tal mesorectal excision (TME). Perioperative treatment of partic-
ipants was not described in most of the trials. Six studies had a
standardised protocol (Hong Kong a 2004; Braga 2007; Ng 2008;
Kang 2010; COLOR 2 b 2011; Liang 2011) and only two had
an enhanced recovery protocol (King 2006; Lujan 2009). Data
on the type of anaesthesia and analgesia were not given in most
studies.
Most studies reported on a range of different outcomes. The most
commonly assessed were overall and disease-free survival rates, lo-
cal recurrence rates, adequacy of oncological resection (margins
and number of lymph nodes removed), duration of surgery, con-
version rate, mortality, morbidity, anastomotic leakage, postoper-
ative pain, gastrointestinal recovery rate and hospital stay. Most
studies lacked a definitionof conversion.Themost commoncauses
for conversion to open surgery were tumour invasion of adjacent
structures or bulky tumours, dense adhesions and technical fail-
ure. Few studies evaluated quality of life (MRCCLASICC a 2005;
MRC CLASICC b 2005; King 2006; Braga 2007; Kang 2010),
immune response (Hong Kong c 2000; MRC CLASICC c 2001;
Hong Kong d 2003; Zhou 2007; COLOR 2 b 2011) or costs
(Hong Kong a 2004; MRC CLASICC a 2005; King 2006; Braga
2007; Ng 2008).
Excluded studies
Sixteen papers were excluded for the following reasons: two studies
were not completely randomised (Leung 1999; Mirza 2008) and
two other studies presented the same data as another included
study (Braga 2002; Braga 2005). Two studies includedparticipants
with benign disease (Milsom 1998; Polle 2007) and two other
studies excluded people treated with TME for low rectal cancer (
Schwenk 1998; Liu 2009). Four studies included colorectal cancer
patients, but did not report the number of rectal cancer patients or
any separate outcomes for rectal cancer (Kim 1998; JCOG 0404
2005; LAPKON II 2009; LaFa 2011). One study presented low-
quality data from a period with a steep learning curve (Pan 2007).
Three more studies turned out not to be prospective RCTs, but
were a comparison with the national registry (Morris 2011), an
economic comparison between UK and USA trials (Stead 2000),
and a single-arm phase II trial (Yamamoto 2008).
Risk of bias in included studies
The risk of bias is described in the Characteristics of included
studies section, and a summary is shown in Figure 2. Of the in-
cluded trials, only one had a low risk of bias on all items and three
scored low on six out of seven domains. Five were of unclear or
low quality, with a high or unclear risk in at least five out of seven
domains.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
10Laparoscopic versus open total mesorectal excision for rectal cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
The method of randomisation was unclear in four trials, and allo-
cation concealment was not described in seven trials. Only seven
trials presented an adequate inclusion and randomisation flow di-
agram, including a description of the loss to follow-up.
Blinding
Because of the nature of the interventions, blinding is not an op-
tion in these trials. Instead of blinding, we assessed whether opera-
tive technique and postoperative care were standardised, and how
outcome data and pathological data were registered. We assessed
standardisation in three studies as inadequate. Outcome registra-
tion was adequate in eight studies and unknown in all other stud-
ies.
Incomplete outcome data
We did not detect any attrition bias. Not all studies reported on
loss to follow-up. Questionnaire response rates were reported for
both groups when eligible.
Selective reporting
Comparing the described protocols and methods to the reported
results of the different studies, we did not find evidence of any
selective reporting, although some studies did not report exact
data on non-significant results mentioned in the text sections. An
overview of studies and outcomes in Table 1 shows that most
studies report on the same outcomes. Five papers reported only
one outcome in a subgroup analysis of another trial and one study
reported only one outcome for the included participant group.
Other potential sources of bias
An important source of bias is the experience of the surgeons
conducting LTME, because of the known steep learning curve. (
Schlachta 2001; Tekkis 2005)When only one experienced surgical
team is involved, this bias can be limited, but it can be extensive in
large multi centre trials or less experienced teams. Only the MRC
CLASICC a 2005 and Kang 2010 defined the experience of their
surgeons as based on at least 20 procedures. Four other studies
only stated that their surgeons were “well experienced” or “the
most experienced” (Hong Kong a 2004; Braga 2007; Pechlivanides
2007; Ng 2008;). The remaining eight did not describe surgeons’
experience at all or stated only a single surgeon or team performed
the procedures.
Effects of interventions
See: Summary of findings for the main comparison
Laparoscopic versus open total mesorectal excision for rectal cancer
Disease-free and overall survival
The disease-free and overall survival rates have been reported in
only six studies including 1494 participants, because of lack of
follow-up in the other eight studies. Two of these are trials that will
report on these results in the near future (Kang 2010; COLOR
2 b 2011), while the other six did not mention any long-term
outcomes in their Methods or protocol.
The combined data for these studies do not show statistical signif-
icant differences in disease-free survival at three ((OR 1.08; 95%
CI 0.67 to 1.74), five (OR 1.02; 95% CI 0.76 to 1.38) and 10
years ((OR 1.25; 95% CI 0.51 to 3.06) Analysis 1.1) for LTME
and OTME. Regarding overall survival at three (OR 1.00; 95%
CI 0.70 to 1.42), five (OR 1.15; 95% CI 0.87 to 1.52) or 10 years
((OR 1.15; 95% CI 0.80 to 1.65); Analysis 1.2), again no differ-
ences could be found between the groups. Braga 2007 could not
be included in the meta-analysis because data were only shown in
a Kaplan-Meier curve, but did not show any differences between
LTME and OTME groups. See Figure 3.
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Figure 3. Forest plot of comparison: 2 Survival and recurrences, outcome: 2.1 Disease free survival.
Ng 2012 has reported the combined 10-year follow-up of Hong
Kong a 2004 and Ng 2008 (n = 278) in a conference abstract,
and reported no statistically significant differences in survival and
recurrences (disease-free survival 82.5% versus 77.6%, P = 0.443,
overall survival 63.0% versus 61.1%, P = 0.505 and locoregional
recurrences 5.5% versus 9.3%, P = 0.296).
Recurrences
There are no statistical significant differences seen in recurrence
rates between LTME and OTME (local OR 0.89; 95% CI 0.57
to 1.39; Analysis 1.3, and distant OR 0.96; 95% CI 0.70 to 1.32;
Analysis 1.4). As for port site metastases, only 11 participants
(0.9%) in the LTME group developed a port site metastasis (
Analysis 1.5). Eight were an extraction site recurrence, leaving
only one true port site metastasis. The other two recurrences were
not specified. Only three studies described the use of a wound
protector in LTME, and reported a similar total of two (0.8%) port
site recurrences (Hong Kong a 2004; Zhou 2004; Kang 2010).
Quality of resection: CRM positivity and number of lymph nodes
retrieved
One of the most important variables for measuring the quality of
the oncological resection and predicting recurrence and survival
are circumferential margin involvement and number of lymph
nodes retrieved. Eleven RCTs describe the number of retrieved
lymph nodes, with no difference between both groups (MD -
0.43; 95% CI -1.13 to 0.26; Analysis 2.1). Eight studies reported
on circumferential margin positivity, with no difference between
LTME andOTME (OR0.99; 95%CI 0.71 to 1.40; Analysis 2.2).
Duration of surgery, incision length and conversion rate
The duration of surgery was longer for LTME in 11 out of 12
included trials for this analysis, with a difference of 37 minutes
(MD 37.48; 95% CI 27.80 to 47.15; Analysis 2.3). Two other
studies did not report on surgical time. Four studies reporting on
incision length all found a shorter incision length for LTME with
a mean difference of 12 centimetres (MD -12.83; 95% CI -14.87
to -10.80; Analysis 2.4).
All studies except two (Zhou 2004; Zhou 2007) describe the con-
version rate for the laparoscopic group (Analysis 2.5). The mean
conversion rate was 14.5% (0% - 34%), and as described in MRC
CLASICC a 2005, is highly dependent on the location of the tu-
mour and the experience of the surgeon. For most studies, the
surgeons’ experience was not clearly stated and therefore cannot
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be compared from these results.
Intraoperative morbidity, blood loss and transfusion requirement
Ten studies described less intraoperative blood loss or transfusion
requirement for LTME with a mean difference of 102 millilitres
(MD -101.78; 95% CI -147.57 to -55.98; Analysis 2.6) and an
odds ratio for transfusion requirement of 0.34 (95% CI 0.19 to
0.62; Analysis 2.7). Only King 2006 described a higher transfu-
sion requirement for LTME, but a lower percentage of partici-
pants with over 100 millilitres of blood loss during surgery (27%
versus 95%, P < 0.001). The overall intraoperative morbidity was
described in four studies and was 11.3% for LTME versus 12.0%
for OTME (OR 0.86; 95% CI 0.62 to 1.18; Analysis 2.8). There
were insufficient data to compare bowel injury, haemorrhage and
solid organ injury separately but individual studies did not show
any differences.
Postoperative morbidity and mortality
The overall complication rate was 29.3% (LTME) and 27.5%
(OTME) (OR 0.94; 95% CI 0.80 to 1.10; Analysis 3.1), with
fewer wound infections and less postoperative bleeding in the
LTME group (OR 0.68; 95% CI 0.50 to 0.93 (Analysis 3.2) and
OR 0.30; 95% CI 0.10 to 0.93 (Analysis 3.3)). We found no dif-
ferences in urinary bladder infection or retention (OR 1.23; 95%
CI 0.83 to 1.81; Analysis 3.4) and pneumonia (OR 1.32; 95% CI
0.83 to 2.09; Analysis 3.5) between both groups. See Figure 4.
Figure 4. Forest plot of comparison: 4 Short term morbidity and mortality, outcome: 4.1 30d morbidity
(total).
Ten studies described similar anastomotic leakage rate for both
groups (7.7% vs 6.3% OR 1.01; 95% CI 0.73 to 1.40; Analysis
3.6), while two other trials only included abdominoperineal resec-
tion and did not have anastomotic leakage as an outcome. Conse-
quently, the need for reoperation was 5.1% and 5.8% (OR 0.82;
95% CI 0.57 to 1.20; Analysis 3.7) in the LTME and OTME
groups respectively. The anastomotic leakage rate has been cor-
rected for participants without an anastomosis.
Data on postoperative mortality were available for 11 studies, with
similar mortality rates for the two treatment groups for individual
and grouped data (OR 0.81; 95% CI 0.50 to 1.32; Analysis 3.8).
Four of them (Zhou 2004; Kang 2010; Liu 2010; Liang 2011)
reported no 30-day mortality in either group.
Postoperative pain
Postoperative pain can be assessed in many different ways. Com-
mon measures are a visual analogical scale (VAS) score, patient-
controlled anaesthesia (PCA) use, days ofmorphine use and epidu-
ral insufficiency requiring opioid use. Six studies reported results
for pain score and analgesic use, and all reported lower analgesic
use in the LTME group (standardised mean difference (SMD) -
0.60; 95% CI -0.93 to -0.27; Analysis 4.1). COLOR 2 a 2013 re-
ported on the percentage of participants using epidural, opioids or
other analgesics, with less epidural use in the LTME group.Three
trials reported on VAS pain scores, with a lower pain score for
LTME at day one (MD -0.74; 95% CI -1.04 to -0.44; Analysis
4.2).
Gastrointestinal recovery and hospital stay
Length of hospital stay was given in 11 studies, and showed a
reduction of two days for the LTME group (MD -2.16; 95% CI -
3.22 to -1.10; Analysis 4.3). This is reflected in the gastrointestinal
recovery rate to a faster resumption of a normal diet (MD -0.52;
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95% CI -0.80 to -0.23; Analysis 4.4), and an earlier first bowel
movement (MD -0.86; 95% CI -1.17 to -0.54; Analysis 4.5) in
the LTME group. See Figure 5.
Figure 5. Forest plot of comparison: 5 Post op recovery, outcome: 5.3 Hospital stay.
Long-term morbidity: Incisional herniae and bowel obstruction
Only three studies reported on long-term morbidity from inci-
sional hernia and intestinal obstruction (MRC CLASICC a 2005;
Braga 2007; Hong Kong b 2009). No statistically significant dif-
ference between OTME and LTME was seen (OR 0.84; 95% CI
0.32 to 2.21; Analysis 5.1). Intestinal obstruction occurred less
frequently in the LTME group (OR 0.30; 95% CI 0.12 to 0.75;
Analysis 5.2).
Quality of life: physical and sexual functioning
Four studies reported on quality of life using questionnaires (MRC
CLASICC a 2005; King 2006; Braga 2007; Kang 2010). Only
two reported on bladder and sexual functioning (MRCCLASICC
a 2005; Kang 2010).
Of the four reporting on physical functioning, three reported sig-
nificantly better functioning in the LTME group at three, six or 12
months. The MRC CLASICC a 2005 showed return to normal
functioning at three months for both groups.
The reports on bladder and sexual functioning suffered from low
response rates, varying from 71% overall response rate down to
10% on specific questions about sexual enjoyment and problems.
Kang 2010 showed a baseline difference in sexual problems, but
better sexual functioning after three months in both groups. In
contrast, male sexual problems were worse three months after
surgery but there was no difference between both groups. The
LTME group had significantly fewer micturition, gastrointestinal
and defecation problems at three months after surgery.
MRC CLASICC a 2005 and MRC CLASICC b 2005 both re-
ported on participants in the CLASICC trial, but used different
populations, questionnaires and time points. MRC CLASICC b
2005 showed worse sexual functioning after LTME, specifically
for erectile dysfunction, but none were statistically significant. No
differences in sexual interest, activity and enjoyment were seen at
any time point, although for women there was a significant de-
crease compared to the preoperative baseline for both groups.
Immune response
Five studies described some short-term differences in immune re-
sponse (MRCCLASICC c 2001;HongKong d 2003; Zhou 2007;
Hong Kong c 2000; COLOR 2 b 2011). They all reported differ-
ent parameters, including C-reactive protein (CRP), white blood
cell count (WBC) and Interleukin-6 (IL-6). Two studies reported
on B-cell, T-cell, cortisol and natural-killer cell (NK-cell) levels.
MRC CLASICC c 2001 had the largest population (n = 161), but
did not show any differences in T-cell, B-cell and NK-cell levels
at day three. Zhou 2007 included 71 participants and the three
other studies around 40 participants each. Hong Kong c 2000
showed higher levels of IL-6 and CRP, with a peak for IL-6 at two
hours (P < 0.001) and CRP at 48 hours (P < 0.01) in the OTME
group. The same results were shown by Zhou 2007, but they were
measured at one and three dayswith a difference for IL-6 at day one
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and for CRP at day one and three for the OTME group. Cortisol
levels and WBC were also higher in the OTME group at day one.
COLOR 2 b 2011 expressed results only as ratios compared to
preoperative values and showed less increase in IL-6 level at two
hours postoperatively in the LTME group. Cortisol, WBC and
CRP did not show any differences at 2, 24 and 72 hours. Finally,
Hong Kong d 2003 did not show any differences at days one and
three for WBC, NK-cell, T-cell and B-cell levels, but for T-cell
and B-cell levels there was less suppression in the LTME group at
day eight.
Costs
An analysis of costs was included in five studies (Hong Kong
a 2004; MRC CLASICC a 2005; King 2006; Braga 2007; Ng
2008). Data were too heterogeneous to be included in a meta-
analysis. Braga 2007 only reported the difference in costs in which
the benefits of LTME could not compensate for the additional
operating room charges, with a mean difference of USD 351 more
for LTME. The four other studies calculated the costs per partic-
ipant randomised. King 2006 and MRC CLASICC a 2005 re-
ported the median direct and indirect costs for LTME. King 2006
reported the costs at GBP 6344 for LTME and GBP 6786 for
OTME resulting in a saving of GBP 353 for LTME while being
the only study in this analysis that used a fast-track programme.
MRC CLASICC a 2005 reported the opposite, with GBP 8259
for LTMEandGBP7820 forOTME, resulting inGBP439higher
costs for LTME. Neither result achieved a statistically significant
difference. Hong Kong a 2004 and Ng 2008 reported only the
direct costs, with means of USD 9297 and USD 9588 for LTME
and USD 7148 and USD 7517 for OTME with a significant dif-
ference of about USD 2000 in favour of OTME.
D I S C U S S I O N
Summary of main results
Nine studies (n = 1877) reported on at least one of the long-term
survival or recurrence outcomes and the meta-analyses as well as
the separate studies showed similar long-term survival and recur-
rence rates for laparoscopic and open total mesorectal excision.
We found a mean difference in hospital stay of two days, with
individual studies reporting a 0.5- to 5-day difference in favour of
LTME. Schwenk 2005 found comparable results for colon cancer
with a mean difference of 1.5 days in favour of the laparoscopic
group. Seven studies standardised their postoperative protocol, but
only two implemented an enhanced recovery programme.
Overall completeness and applicability of
evidence
Benefits of laparoscopic surgery are attributable to causing less sur-
gical trauma to the patient, which has a positive effect on surgery-
induced immunosuppression. This can be demonstrated by taking
measurements after surgery, with different peak moments for sev-
eral parameters. The included studies in this review did not take
measurements at the same time point, which may explain why not
all of them could show differences in similar parameters. Reduced
immunosuppression could be related to a lower complication rate
and to shorter hospital stay, and may reduce development of post-
operative metastasis (although this has yet to be shown in a ran-
domised trial (Hogan 2011)).
The includedRCTs include studies and subgroups of patients with
low, mid and high rectal cancer and both APR and anterior resec-
tions with and without anastomosis. These differences can affect
outcomes, especially the various techniques for low rectal resec-
tions can influence the circumferential margins and therefore lo-
cal recurrences and survival. Lack of reporting of the CRM is an
important issue with only eight out of fourteen studies describing
this outcome. The number of retrieved lymph nodes is described
by eleven studies but is more dependent on difference in high and
low vascular ligations of the mesentery than on open or laparo-
scopic surgery. (Kessler 2013)
With a mean age between 44 and 72, three studies including T4
carcinoma and six offering neoadjuvant treatment in selected cases
and a tumour localisation between 15 cm and the anal verge, there
is a fair amount of heterogeneity among the included studies.
Especially the early and smaller studies included a younger and
healthier study population compared to the average rectal cancer
patient. Of the four ongoing trials (n = 470 to 1100 participants),
three (Kang 2010; ACTRN12609000663257; NCT00726622)
require neoadjuvant treatment for selected stages of rectal cancer
and the fourth (COLOR 2 a 2013) stratifies the randomisation
for neoadjuvant treatment. This might influence both long term
and short term outcomes as only six offered neoadjuvant ther-
apy in this review. All ongoing studies include abdominoperineal
resections as well as (low) anterior resections, but the maximum
distance from the anal verge varies between 9 cm (Kang 2010),
12 cm (NCT00726622) and 15 cm (ACTRN12609000663257;
COLOR 2 a 2013).
Another important difference between the included RCTs and
current practise are the fast track recovery programmes such as
the enhanced recovery after surgery (ERAS) programme. Only
two included studies describe an enhanced recovery programme
(King 2006; Lujan 2009). COLOR 2 a 2013 referred to local
protocols, whereas the other two ongoing studies do not describe
their postoperative protocol in the online summary. The LAFA
trial (Vlug 2011) showed laparoscopic surgery in combination
with fast track recovery resulted in the fastest recovery and hospital
discharge compared to regular care and open surgery.
Quality of the evidence
Since 1998, 14 RCTs have been published to answer the ques-
tion whether LTME results in better short-term results and at least
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equal long-term oncological results. The quality of these studies
varied extensively, as did the number of included participants. Al-
though the total mesorectal excision principle has been established
since 1986, treatment protocols have changed. Surgeons gained
more experience in laparoscopic colon and rectal cancer surgery,
fast-track protocols were introduced and neoadjuvant treatment
became a standard of care in a proportion of cases. All of these
factors are able to influence the long-term results of these trials;
however they should influence both the laparoscopic and open
groups equally, except for the learning curve for laparoscopic pro-
cedures.
The quality of the evidence for the most important outcomes was
moderate (Summary of findings for the main comparison). This
means that further research is likely to have an important impact
on our confidence in the estimate of effect and may change the
estimate. The main reason is the imprecision of the confidence
intervals, they allow for a variability in odds ratios up to 40% on
both sides, which contributes to an absolute increase or decrease
of 6% in disease free survival, 5% in overall survival, 2% in local
recurrences, and 3% in 30-day morbidity. The COLOR 2 a 2013
trial used a 5% margin for local recurrences for their non-inferi-
ority design, therefore our results remain within those limits.
Potential biases in the review process
Publication bias is a threat for any systematic review. We believe
we have missed no important randomised controlled trials after
screening reference lists of included trials and other relevant stud-
ies and reviews, in addition to the extensive systematic searching
of electronic databases and trials registers. We have described all
registered ongoing trials.
In the current literature regarding learning curves in laparoscopic
colorectal surgery, a wide range of numbers of procedures is re-
ported until a flat curve is achieve, ranging from 11 to 15 colec-
tomies (Simons 1995), 30 colorectal resections (Schlachta 2001)
and 60 to 65 colectomies (Tekkis 2005). For the open total
mesorectal excision (OTME) technique, the cut-off point for per-
centage of clear resection margins is defined as around 50 proce-
dures (Oh 2011). This suggests that only the surgeons in Kang
2010 are assumed to have had sufficient experience for a good
laparoscopic resection and results may further improve over time.
Agreements and disagreements with other
studies or reviews
A meta-analysis of RCTs on laparoscopic and open colorectal
surgery (Sammour 2011) has shown a higher intraoperative com-
plication rate for laparoscopic surgery of 6.3% versus 3.9% for
open surgery (OR)1.55, 95%CI 1.12 to 2.15). The rate of bowel
perforations was 2.1% versus 0.9% (OR 2.28, 95% CI 1.27 to
4.10) across 3018 participants. These differences had limited ef-
fect on the outcome, with an average postoperative complication
rate of 28%. Compared to the intraoperative complication rate of
11.3% in LTME versus 12.0% in OTME in four included stud-
ies in our review (n = 1618), we cannot confirm these previously
reported complication rates for LTME.
The results of this review confirm what other colorectal and rec-
tal trials have suggested: short-term results are similar with faster
recovery in the LTME group and no statistically significant dif-
ferences were found in the long-term oncological results. For
rectal cancer, non-randomised trials have suggested oncological
safe resections as presented in the previous version of this review
(Fleshman 1999; Feliciotti 2003; Breukink 2006). Since then, sev-
eral other reviews have been published describing the same results.
Aziz 2006, Gao 2006, Anderson 2008 and Poon 2009 included
mainly non-randomised trials, and Row 2010 was a literature re-
view. Ohtani 2011, Huang 2011 and Trastulli 2012 were the first
to include only randomised trials. However, Ohtani 2011 also in-
cluded three non-randomised trials, Huang 2011 included only
six trials and Trastulli 2012 nine trials, whereas this systematic
review was able to identify 14. In addition, the Cochrane review
of laparoscopic colorectal cancer (Kuhry 2008) presented separate
meta-analyses for four included rectal cancer RCTs.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently moderate quality evidence that laparoscopic to-
tal mesorectal excision (TME) has similar effects to open TME
on long term survival outcomes for the treatment of rectal cancer.
The quality of the evidence was downgraded due to imprecision
and we cannot rule out either approach being superior. There is
moderate quality evidence that it leads to better short-term post-
surgical outcomes in terms of recovery for non-locally advanced
rectal cancer and shorter hospital stay. Currently results are con-
sistent in showing a similar disease-free survival and overall sur-
vival, and for recurrences after at least three years and up to 10
years although due to imprecision we cannot rule out superiority
of either approach. We await long-term data from a number of
ongoing and recently completed studies to contribute to a more
robust analysis of long-term disease free, overall survival and local
recurrence.
Implications for research
The evidence presented in this systematic review is sufficient to
establish the overall and long-term oncological safety of laparo-
scopic TME. However, at this moment the available data are still
insufficient to confirm these results for subgroups such as ab-
dominoperineal resections, following neoadjuvant therapy, in lo-
cally advanced disease and in combination with fast track recovery
protocols.
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C H A R A C T E R I S T I C S O F S T U D I E S




Number of patients assessed for eligibility but not randomised: unknown
Inclusion period: September 1997 to September 2000
Participants n = 28 (LTME n = 13; OTME n= 15)
Inclusion criteria: primary rectal cancer suitable for APR, incomplete response after
chemoradiation
Exclusion criteria: metastases
Age (y): 59.1 vs 56.4 (mean)
Dukes stage (%): A 39 vs 43; B 38 vs 21; C 23 vs 36; D 0 vs 0
Tumour location: distal rectum
Follow-up: 47.2 months (mean)




Neoadjuvant therapy: all chemoradiation
Outcomes No primary outcome stated
Length of follow-up, local and distant recurrences
Duration of surgery, need for transfusion, postoperative hospital stay, postoperative com-
plications, need for reoperation, number of lymph nodes
Notes Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “were randomised to undergo treatment”
Allocation concealment (selection bias) Unclear risk Unknown, moment of randomisation un-
known
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up not described, intention-
to-treat not described
Selective reporting (reporting bias) High risk No primary outcome stated, not all data
given as described in Methods section
No sample size calculation
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Araujo 2003 (Continued)
Other bias High risk Published in a non-peer-reviewed journal,
Low diversity with distal rectal cancer only
Surgeon’s experience unknown
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Surgical procedure described according to
TME
Postoperative protocol unknown
Blinding of outcome assessment (detection
bias)
All outcomes




Number of patients assessed for eligibility but not randomised: 28
Inclusion period: unknown
Participants n = 168 (LTME n = 83; OTME n = 85)
Inclusion criteria: age > 18, histologically confirmed rectal cancer, suitable for elective
surgery
Exclusion criteria: clinical infiltrative cancer, cardiovascular dysfunction, respiratory dys-
function, hepatic dysfunction, ongoing infection, plasma neutrophil level < 2 x10ˆ9
Age (y): 62.8 vs 65.3 (mean)
Dukes stage (%): A 30 vs 28; B 19 vs 22; C 38 vs 34; D 13 vs 15
Tumour location: rectum < 15 cm
Follow-up: 53.6 months (mean)
Interventions Laparoscopic vs open TME
APR (%): 8 vs 13
AR (%): 92 vs 87
Colon (%): 0
Neoadjuvant therapy: chemoradiation (T3 only)
Outcomes Primary outcome: Short-term postoperative morbidity
Cost benefit analysis, quality of life, oncological outcome
Notes Enlarged subgroup from Braga 2002
Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated list, sealed envelopes
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Braga 2007 (Continued)
Allocation concealment (selection bias) Low risk Opened before induction of anaesthesia
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up, intention-to-treat
analysis
Selective reporting (reporting bias) Low risk Survival given per stage, not combined and
only in Kaplan-Meier curve
Sample size calculation performed
Other bias Low risk Same surgical team, “well experienced”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure according to TME
Standardised postoperative protocol and
discharge
criteria, no enhanced recovery
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Complications registered by independent
team,
weekly clinic visits until 30 days
COLOR 2 a 2013
Methods Multicentre RCT (30 academic centres)
Belgium, Canada, Denmark, Germany, The Netherlands, Spain, South Korea, Sweden
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: January 2004 to May 2010
Participants n = 1044 (LTME n = 699; OTME n = 345)
Inclusion criteria: Solitary rectal cancer at colonoscopy or barium enema x-ray, distal
border within < 15 cm of anal verge, suitable for elective surgery, informed consent
Exclusion criteria: Metastatic disease, local resection, T4 tumours, T3 tumours with
margins < 2 mm to endopelvic fascia on CT or MRI, other malignancy than adeno-
carcinoma, participant < 18 y, acute intestinal obstruction, > 1 colorectal tumour, FAP,
HNPCC, Crohn’s disease or ulcerative colitis, ASA > III, pregnancy
Age (y): 66.8 vs 65.8 (mean)
Gender (male): 64% vs 61%
Dukes stage (%): A 30 vs 29; B 31 vs 33; C 38 vs 38
Tumour location: rectum <15cm
Follow-up: short term data, 28 days
Interventions Laparoscopic vs open TME
APR (%): 29 vs 23
LAR (%): 70 vs 77
Colon (%): 0
Neoadjuvant therapy: radiotherapy 59% vs 58%, chemotherapy 32% vs 34%
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COLOR 2 a 2013 (Continued)
Outcomes Primary outcome: local recurrences at 3 years (will be published later)
Secondary outcomes: Operating time, conversion rate, blood loss, postoperative recov-
ery of gastrointestinal function, postoperative pain medication, length of hospital stay,
morbidity and mortality within 28 days after surgery, histopathological outcomes and
anastomotic leakage
Notes COLOR2 b 2011 presents a local subgroup of 40 participants focusing on inflammatory
response markers
Funding or conflicts of interest: Funding by Ethicon Endo-Surgery Europe, Swedish
Cancer Foundation, West Gothia Region and Sahlgrenska University Hospital. The
authors declare to have no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised via online register
with randomisation list stratified for cen-
tre, tumour location and preoperative ra-
diotherapy
Allocation concealment (selection bias) Low risk Central randomisation after registration in
database
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis
Selective reporting (reporting bias) Low risk Sample size calculation performed
Other bias Low risk Surgeon’s technique and resection quality
assessed prior to enrolment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Local standardised postoperative protocols
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Objective measurements
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COLOR 2 b 2011
Methods Single-centre RCT (University Hospital)
Amsterdam, The Netherlands
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: June 2006 to December 2008
Participants n = 40 (LTME n = 22; OTME n = 18)
Inclusion criteria: Solitary rectal cancer at colonoscopy or barium enema x-ray, distal
border within < 15 cm of anal verge, suitable for elective surgery, informed consent
Exclusion criteria: Metastatic disease, local resection, T4 tumours, T3 tumours with
margins < 2 mm to endopelvic fascia on CT or MRI, other malignancy than adenocarci-
noma, patient < 18 y, acute intestinal obstruction, > 1 colorectal tumour, FAP, HNPCC,
Crohn’s disease or ulcerative colitis, ASA > III, pregnancy
Age (y): 64 vs 67 (median)
Gender (male): 73% vs 67%
Dukes stage (%): A 50 vs 27.8; B 22.3 vs 38.9; C 22.3 vs 22.2
Tumour location: rectum < 15 cm
Follow-up: 72 h
Interventions Laparoscopic vs open TME
APR (%): 18 vs 28
LAR (%): 82 vs 72
Colon (%):0
Neoadjuvant therapy: unknown
Outcomes Primary outcomes :Postoperative inflammatory response (IL-6, IL-8, CRP), immune
status (WBC, HLA-DR), stress response (cortisol, prolactin, growth hormone)
Secondary outcomes: Hospital stay, complication rate, lymph nodes resected
Notes Local subgroup of COLOR 2 a 2013
Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomisedwithinCOLORII
trial, computer-generated list, stratified for
preoperative radiotherapy and location of
tumour
Allocation concealment (selection bias) Low risk Randomisation after entry of participant
details in database
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis
Selective reporting (reporting bias) Unclear risk No sample size calculation for this sub
study
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COLOR 2 b 2011 (Continued)
Other bias High risk Surgeon’s experience: unknown
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Standardised postoperative protocol per
hospital
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective measurements
Hong Kong a 2004
Methods Two-centre RCT
Hong Kong, China
Number of patients assessed for eligibility but not randomised: 422
Inclusion period: September 1993 to October 2002
Participants n = 403 (LTME n = 203; OTME n = 200)
Inclusion criteria: sigmoid and upper rectal cancer
Exclusion criteria: distance from anal verge < 5 cm, tumour size > 6 cm, T4 rectal cancer,
previous abdominal operations in lower pelvis, intestinal obstruction or perforation,
metastatic disease, no informed consent
Age (y): 67.1 vs 66.5 (mean)
Dukes stage (%): A 15 vs 14; B 35 vs 37; C 32 vs 35; D 18 vs 14
Tumour location: sigmoid and rectum >5 cm
Follow-up: 52.7 vs 49.2 months (median, participants alive)




(Neo)adjuvant therapy: 8.4 vs 13.5 adjuvant radiotherapy, 18.7 vs 25.0 adjuvant che-
motherapy
Outcomes Primary outcome: 5-year disease-free survival,
Secondary outcomes: operation time, disposable instruments used, blood loss, transfu-
sion requirement, analgesic requirement, visual analogue scale, time to flatus, time to
opening bowel, time to normal diet, duration of hospital stay, 30-day mortality, mor-
bidity
Notes Short-term data rectosigmoid subgroup
Funding or conflicts of interest: The authors declare no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
27Laparoscopic versus open total mesorectal excision for rectal cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hong Kong a 2004 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Kept concealed by an independent operat-
ing theatre co-ordinator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up described, intention-to-
treat analysis
Selective reporting (reporting bias) High risk Sample size calculation performed
Ratio between sigmoid and rectal cancer
not given
Other bias High risk High diversity rectosigmoid carcinoma, ra-
tio not given
Surgeon’s experience: “Skilled in both la-
paroscopic and open colorectal surgery”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure described
Standardised postoperative protocol (no
enhanced recovery programme)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Hong Kong b 2009
Methods Two-centre RCT
Hong Kong, China
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: September 1993 to October 2002
Participants n = 153 (LTME n = 76; OTME n = 77)
Inclusion criteria: upper rectal cancer
Exclusion criteria: distance from anal verge < 5 cm, tumour size > 6 cm, T4 rectal cancer,
previous abdominal operations in lower pelvis, intestinal obstruction or perforation,
metastatic disease, no informed consent
Age (y): 66.5 vs 65.7 (mean)
Dukes stage (%): A 14 vs 17; B 38 vs 38; C 26 vs 36; D 21 vs 9
Tumour location: Upper rectum 12 - 15 cm
Follow-up: 112.5 vs 108.8 months (median, living participants)




Adjuvant therapy (%): 14.5 vs 32.5 chemotherapy, 17.1 vs 27.3 radiotherapy
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Hong Kong b 2009 (Continued)
Outcomes Primary outcome: Long-termmorbidity (adhesion-related obstruction, incisional hernia)
Secondary outcomes: Recurrence and survival
Notes Long-term data upper rectal cancer subgroup of Hong Kong a 2004
Short-term mortality not included in long-term morbidity and mortality analysis
Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk as Hong Kong a 2004
Allocation concealment (selection bias) Low risk as Hong Kong a 2004
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up described, intention-to-
treat analysis
Selective reporting (reporting bias) Low risk Low diversity with upper rectal subgroup
Other bias High risk as Hong Kong a 2004
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk as Hong Kong a 2004
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Hong Kong c 2000
Methods Single-centre RCT
Hong Kong, China
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: September 1996 to April 1998
Participants n = 34 (LTME n = 17 ; OTME n = 17 )
Inclusion criteria: sigmoid and upper rectal cancer
Exclusion criteria: distance from anal verge < 5 cm, tumour size > 6 cm, T4 rectal cancer,
previous abdominal operations in lower pelvis, intestinal obstruction or perforation,
metastatic disease, no informed consent
Age (y): 67.0 vs 66.9 (mean)
Dukes stage (%): A 0 vs 0; B 59 vs 53; C 41 vs 47; D 0 vs 0
Tumour location: sigmoid and rectum
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Hong Kong c 2000 (Continued)
Follow-up: 22.6 vs 20.5 months (median)




Outcomes Primary outcome: cytokine and CRP response
Notes Smaller subgroup rectosigmoid Hong Kong a 2004
Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk as Hong Kong a 2004
Allocation concealment (selection bias) Low risk as Hong Kong a 2004
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data reported, intention-to-
treat analysis
Selective reporting (reporting bias) Low risk Sample size calculated
Other bias High risk High diversity with sigmoid and rectum
carcinoma, ratio not given
Low conversion rate compared to Hong
Kong a 2004
Surgeon’s experience: “Skilled in both la-
paroscopic and open colorectal surgery”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk as Hong Kong a 2004
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective measurements
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Hong Kong d 2003
Methods Single-centre RCT
Hong Kong, China
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: June 1998 to August 1999
Participants n = 40 (LTME n = 20; OTME n = 20)
Inclusion criteria: sigmoid and upper rectal cancer
Exclusion criteria: distance from anal verge < 5 cm, tumour size > 6 cm, T4 rectal cancer,
previous abdominal operations in lower pelvis, intestinal obstruction or perforation,
metastatic disease, no informed consent
Age (y): 68.2 vs 69.1 (mean)
Dukes stage (%): A 5 vs 5, B 50 vs 55, C 45 vs 40, D 0 vs 0
Tumour location: sigmoid and rectum
Follow-up: 8 days




Outcomes Primary outcome: lymphocyte subpopulation and natural killer cell cytotoxicity
Notes Smaller subgroup rectosigmoid Hong Kong a 2004
Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk as Hong Kong a 2004
Allocation concealment (selection bias) Low risk as Hong Kong a 2004
Incomplete outcome data (attrition bias)
All outcomes
Low risk no missing data reported, intention-to-
treat analysis
Selective reporting (reporting bias) Low risk Sample size calculated
Other bias High risk High diversity rectosigmoid carcinoma, ra-
tio not given
Surgeon’s experience: “Skilled in both la-
paroscopic and open colorectal surgery”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk as Hong Kong a 2004
31Laparoscopic versus open total mesorectal excision for rectal cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hong Kong d 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective measurements
Kang 2010
Methods Multicenter RCT (3 centres)
Seoul, South Corea
Number of patients assessed for eligibility but not randomised: 39
Inclusion period: April 2006 to August 2009
Participants n = 340 (LTME n = 170; OTME n =170)
Inclusion criteria: Mid and low rectal cancer, after preoperative chemoradiation
Exclusion criteria: Distant metastasis, another malignancy, severe cardiac or pulmonary
disease, pregnancy, severe medical disease, intestinal obstruction or perforation
Age (y): 57.8 vs 59.1 (mean)
Dukes stage (%): unknown (cT3 N0-2 M0)
Tumour location: mid or lower rectum < 9cm
Follow-up: 3 months
Response rate for questionnaire 75% vs 77%
Interventions Laparoscopic vs open TME
APR (%): 11.2 vs 14.1
LAR (%): 88.8 vs 85.9
Colon (%): 0
Neoadjuvant therapy: All neoadjuvant chemoradiotherapy and recommended 4 months
adjuvant therapy
Outcomes Primary outcome: 3-year disease-free survival
Secondary outcomes: TME quality, CRM, lymph nodes, distance anal verge, surgical
time, length of incision, tumour size, gastrointestinal recovery, hospital stay, complica-
tions, quality of life
Notes Long-term data expected in 2013
Funding or conflicts of interest: National cancer centre, South Corea. The authors de-
clared no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Telephone trial co-ordinator, block permu-
tation approach
Allocation concealment (selection bias) Unclear risk Telephone trial co-ordinator, moment of
randomisation unknown
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Kang 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up, intention-to-treat
analysis
Selective reporting (reporting bias) Low risk No missing data
Sample size calculation performed
Other bias Low risk Low diversity with mid/low rectal cancer
cT3N0-2
Surgeon’s experience: median 75 laparo-
scopic resections (28 - 150), live demon-
strations and video assessment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure according to TME
Standardised postoperative protocol, no
enhanced recovery
Blinding of outcome assessment (detection
bias)
All outcomes




Number of patients assessed for eligibility but not randomised: 32
January 2002 to March 2004
Participants n = 62 (LTME n = 41; OTME n = 19) (rectal n = 19)
Inclusion criteria: adenocarcinoma of the colon or rectum
Exclusion criteria:Non-elective admission, distant metastases, age < 18, pregnancy, no
informed consent, unsuitable for epidural anaesthesia (from 2nd year on)
Age (y): 72.3 vs 70.4 (mean)
Dukes stage (%): A 22.0 vs 5.3; B 46.3 vs 57.9; C 31.7 vs 36.8
Tumour location: colon and rectum
Follow-up: 6 weeks/12 months
Compliance rate for HRQL questionnaires over 95% and response rate of 80%
Interventions Laparoscopic vs open TME
APR (%): 7.3 vs 5.3
LAR (%): 29.3 vs 21.1
Colon (%): 63.4 vs 73.7
Neoadjuvant therapy:12% neoadjuvant chemotherapy, 35% adjuvant chemotherapy
Outcomes Primary outcome: Hospital stay
Secondary outcomes: Morbidity, analgesia requirement, antiemetic requirement, re-ad-
mission stay, quality of life, cost, disease recurrence, stoma closure, adjuvant chemother-
apy, health-related quality of life and functional outcomes
Study-specific questionnaire for functional recovery
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King 2006 (Continued)
Notes Funding or conflicts of interest: National Health Service Developments in the Organi-
zation of Care Projects Grant
Yeovil District Hospital has received funds from Ethicon Endosurgery to support post-
graduate training in
laparoscopic surgery. One author is supported by a Medical Research Council Clinician
Scientist Award
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Unclear risk Telephone trial co-ordinator, moment of
randomisation unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up described, intention-to-
treat analysis
Selective reporting (reporting bias) Low risk Data reported according to methods de-
scribed
No sample size for these outcomes calcu-
lated
Other bias Unclear risk High diversity, all colorectal patients
Single surgeon, experience unknown
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure described according to
TME
Postoperative protocol according to en-
hanced recovery programme
Blinding of outcome assessment (detection
bias)
All outcomes




Number of patients assessed for eligibility but not randomised: 3
Inclusion period: May 2004 and April 2008
Participants n = 343 (LTME n = 169; OTME n = 174)
Inclusion criteria: rectal cancer confirmed by pathological examination, written informed
consent. Suitable for LAR or APR
Exclusion criteria: metastatic disease, BMI > 30, acute intestinal obstruction, previous
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Liang 2011 (Continued)
abdominal surgery, neoadjuvant chemotherapy
Age (y): 57.3 vs 57.4 (mean)
Dukes stage (%): A 5.3 vs 4.0; B 42.6 vs 48.3; C 52.1 vs 47.7; D 0 vs 0
Tumour location: rectum
Follow-up: 44 months (median)
Interventions Laparoscopic versus open TME
APR (%): 49.1 vs 40.2
LAR (%): 50.9 vs 59.8
Colon(%): 0
(neo)adjuvant therapy: neoadjuvant excluded, adjuvant unknown
Outcomes Primary outcome: 3-year survival
Secondary outcomes: Number of lymph nodes removed, length of specimen, distance
between inferior border of tumour and incised margin in LAR, time to first discharge,
bowel movement and fluid intake, infectious complications, anastomotic leakage, anas-
tomotic stenosis, deep vein thrombosis, 1-year survival
Notes Funding or conflicts of interest: No competing financial interests declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation not mentioned
Allocation concealment (selection bias) Low risk Sealed opaque envelopes, day before
surgery
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up described, intention-to-
treat analysis
Selective reporting (reporting bias) High risk Sample size calculation not performed
Other bias Unclear risk Distance for anal verge unknown
Single surgical team
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure not described, TME
principles followed
Standardised postoperative protocol (no
enhanced recovery programme)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Complications assessed by reviewer un-
aware of treatment group
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Number of patients assessed for eligibility but not randomised unknown
Inclusion period: February 2005 and October 2008
Participants n = 186 (LTME n = 98; OMTE n = 88)
Inclusion criteria: rectal carcinoma
Exclusion criteria: synchronous cancer, acute intestinal obstruction or perforation
Age (y): 59.3 vs 61.5 (mean)
Dukes stage (%): A 32.7 vs 28.4 B 35.7 vs 34.1 C 27.6 vs 26.1D 4.1 vs 11.4
Tumour location: rectum
Follow-up: 16.3 months (mean)
Interventions Laparoscopic vs open TME, hand-assisted
APR (%): 12.2 vs 15.9
LAR (%): 83.7 vs 79.5
Colon (%): 0
Neoadjuvant therapy: unknown
Outcomes Primary outcome: “safety and efficacy”
Secondary outcomes: Duration of surgery, incision length, blood loss, analgesia require-
ment, time to flatus, time to oral fluids, hospital stay, complications, number of lymph
nodes
Notes Hand-assisted laparoscopy
Funding or conflicts of interest: The authors declared no conflicts of interest in relation
to this article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) High risk Unknown
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up not described, intention-
to-treat irrelevant with no conversions
Selective reporting (reporting bias) High risk Sample size calculation not performed
Other bias Unclear risk Distance from anal verge unknown
Single surgical team, experience unknown
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Surgical procedure described, TME un-
known
No standardised postoperative protocol
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Liu 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes




Number of patients assessed for eligibility but not randomised: 31
Inclusion period: January 2002 and February 2007
Participants n = 204 (LTME n = 103; OTME n = 101)
Inclusion criteria: Mid and low rectal adenocarcinoma
Exclusion criteria: Locally advanced disease, FAP, emergency surgery
Age (y): 67.8 vs 66.0 (mean)
Dukes stage (%): A 10.9 vs 14.6 B 34.7 vs 37.9 C 44.6 vs 42.7 D 9.9 vs 4.9
Tumour location: rectum < 9cm
Follow-up: 32.8 vs 34.1 months (mean)
Interventions Laparoscopic vs open TME
APR (%): 23.8 vs 21.4
LAR (%): 76.2 vs 78.6
Colon (%): 0
Neoadjuvant therapy: Stage II and III neoadjuvant chemoradiotherapy, stage III and IV
adjuvant chemotherapy
Outcomes Primary outcome: number of lymph nodes harvested
Secondary outcomes: 2- and 5-year local recurrence, survival, circumferential margin
involvement, complication rate, hospital stay
Notes Funding or conflicts of interest: The authors declare no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation
Allocation concealment (selection bias) Low risk Sealed envelope until day of operation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up described, intention-to-
treat
analysis
Selective reporting (reporting bias) Unclear risk Non-radical resections excluded from anal-
ysis
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Lujan 2009 (Continued)
Sample size calculation performed
Other bias Unclear risk Single surgical team, experience unknown
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure described according to
TME
Standardised postoperative protocol within
enhanced recovery program
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Single experienced pathologist
MRC CLASICC a 2005
Methods Multicenter RCT (27 centres)
United Kingdom
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: July 1996 to July 2002
Participants n = 794 (381 rectal LTME n = 253; OTME n = 128 )
Inclusion criteria: Colorectal carcinoma suitable for right hemicolectomy, left hemicolec-
tomy, sigmoid, anterior resection, APR
Exclusion criteria: Transversum, cardiac or pulmonary disease, acute intestinal obstruc-
tion, other malignant disease in past 5 years, synchronous adenocarcinoma, pregnancy,
associated GI disease needing surgical intervention
Age (y): 69 vs 69 (mean)
Dukes stage (%): A 16.7 vs 16.4; B 34.6 vs 36.9 C 37.1 vs 34.7
Tumour location: colon and rectum
Follow-up: 3 months, 3 years ,5 years and 10 years
Interventions Laparoscopic vs open colorectal surgery
APR (%): 13 vs 12
LAR (%): 37 vs 36
Colon (%): 50 vs 52
Neoadjuvant therapy(%): Adjuvant radiotherapy 5.5 vs 6.7 and adjuvant chemotherapy
28.1 vs 28.7
Outcomes Primary outcomes: resection margins, Dukes C2 tumours, in-hospital mortality, 3 and
5 year OS/DFS and local recurrence
Secondary outcomes: Complication rates, quality of life, transfusion requirements, dis-
tant and port site recurrences at 3 and 5 years, short term costs
Notes Short term results, short-term costs, 3-year, 5-year and 10-year data of the CLASICC
Trial across 5 different publications.
No reply to request for additional data for meta-analysis
Funding or conflicts of interest: The authors declare to have no conflict of interest. The
trial was funded by the UK Medical Research Council
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MRC CLASICC a 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Telephone trial co-ordinator, stratified by
surgeon, site of surgery, presence of metas-
tases and preoperative radiotherapy
Allocation concealment (selection bias) Low risk Telephone trial co-ordinator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up and missing data de-
scribed, intention-to-treat analysis
Selective reporting (reporting bias) High risk High rate ofmissing participant and patho-
logical data, up to 13%
Sample size calculation performed, but not
reached
Other bias Low risk High diversity with colorectal cancer pa-
tients, specific rectal cancer data published
separately
Surgeons’ experience: a minimum of 20 la-
paroscopic resections
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Surgical procedure according to surgeons
current practice
No standardised postoperative protocol de-
scribed, enhanced recovery unknown
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data monitoring committee
MRC CLASICC b 2005
Methods Multicenter RCT (27 centres)
United Kingdom
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: July 1996 to July 2002
Participants n = 148 (LTME n = 98; OTME n =50), n = 347 including laparoscopic colon group
Age (y): 66 vs 65 (mean)
Questionnaire response rate 71.2% of 347 participants eligible for inclusion
Tumour location: rectum > 5 cm
Interventions Laparoscopic colon versus laparoscopic rectal versus open rectal
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MRC CLASICC b 2005 (Continued)
Outcomes Primary outcome: Overall function score for sexual and bladder function
I-PSS, IIEF, FSFI questionnaires over the last 4 weeks at a single time point within or
after 12 months (up to 76 months)
EORTC module QLQ-CR38 questionnaire items at 2 weeks and 3, 6, 18 months
Notes Subgroup of MRC CLASICC a 2005
Converted patients analysed as open surgery
Some comparisons only between laparoscopic rectal and laparoscopic colon
Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk as MRC CLASICC a 2005
Allocation concealment (selection bias) Low risk as MRC CLASICC a 2005
Incomplete outcome data (attrition bias)
All outcomes
High risk No intention-to-treat analysis
Selective reporting (reporting bias) High risk Most data only addressed in text, numbers
not given
Sample size calculated for questionnaire
outcome
Other bias Unclear risk No other bias identified




Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Validated questionnaires
MRC CLASICC c 2001
Methods Single-centre RCT
Singapore
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: March 1997 to August 1999
Participants n = 236 (LTME n = 118; OTME n = 118)
Inclusion criteria: > 18 y, elective surgery, left hemi colon, sigmoid or rectum
Exclusion criteria: transverse colon, contraindication for pneumoperitoneum, acute in-
testinal obstruction, any malignancy in previous 5 y, synchronous adenocarcinomas and
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MRC CLASICC c 2001 (Continued)
pregnancy
Age (y): 64 vs 62 (median)
Gender (%): male 52 vs 59
Dukes stage (%): A 8 vs 7; B 41 vs 45; C 38 vs 38; D 13 vs 10
Tumour location: colon and rectum
Follow-up: 3 days for immune response
Interventions Laparoscopic vs open colorectal surgery
APR (%): 85 vs 85
AR (%): 6 vs 5
Colon (%):9 vs 10
Neoadjuvant treatment: unknown
Outcomes Primary outcome: T-cell number
Secondary outcomes: CD4, CD8, humoral response, complement level, phagocytosis
function
Notes Singapore subgroup MRC CLASICC a 2005
Funding or conflicts of interest: Funding by the National Reseach Council Singapore,
no statement on conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central telephone randomisation
Allocation concealment (selection bias) Low risk Blocks of 6 and 4
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis, missing data
addressed
Sample size calculation performed
Selective reporting (reporting bias) High risk High rate of missing data (12 participants
preoperative, 44 postoperative)
Other bias Unclear risk 1:1 randomisation, in contrast to 2:1 ran-
domisation in CLASICC Trial
Surgeons’ experience as MRC CLASICC a
2005 > 20 procedures
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure described according to
TME
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective measurements
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Number of patients assessed for eligibility but not randomised: 54
Inclusion period: September 1994 to February 2005
Participants n = 99 (LTME n = 51; OTME n = 48)
Inclusion criteria: Low rectal cancer, eligible for APR
Exclusion criteria: Tumour > 6 cm, clinical infiltrative cancer, recurrent disease, no
informed consent, intestinal obstruction or perforation
Age (y): 63.7 vs 63.5 (mean)
Dukes stage (%): A 5 vs 4; B 6.5 vs 4; C 8.5 vs 10; D 5.5 vs 6
Tumour location: low rectal cancer < 5 cm
Follow-up 87.2 vs 90.1 months (median, participants alive)




Neoadjuvant therapy not offered, adjuvant unknown
Outcomes Primary outcome: Analgesic requirement and postoperative recovery
Secondary outcomes: Recurrence and survival at 5 years
Operative time, blood loss, disposable instruments, transfusion, analgesic requirement,
pain score, time to flatus, time to bowel movement, time to diet, time to walk indepen-
dently, hospital stay, morbidity, mortality, circumferential margin involvement, lymph
nodes
Notes Low and mid rectal cancer subgroup
Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Kept concealed by an independent operat-
ing theatre co-ordinator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis, loss to follow-
up described
Selective reporting (reporting bias) Low risk Follow-up for participants alive
Sample size calculation performed
Other bias Low risk Surgeons’ experience: “surgeons experi-
enced in both laparoscopic and colorectal
surgery”
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Ng 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure, TME unknown
Standardised postoperative protocol, no
enhanced recovery
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Pechlivanides 2007
Methods Multicenter RCT (3 centres)
Crete and Athens, Greece
Number of patients assessed for eligibility but not randomised unknown
Inclusion period: unknown
Participants n = 73 (LTME n = 34; OTME n = 39)
Inclusion criteria: low rectal carcinoma < 12 cm
Exclusion criteria: Tumours extending to the pelvic walls or organs
Age (y): 72 vs 69 (median)
Dukes stage (%): only T stage given
Tumour location: mid and low rectal carcinoma < 12 cm
Follow-up: no follow-up
Interventions Laparoscopic vs open TME
APR (%): 20.6 vs 10.3
LAR (%):79.4 vs 89.7
Colon (%): 0
(Neo) adjuvant therapy: Short-course radiotherapy or long-course chemoradiation
Outcomes Primary outcome: Oncological clearance (number of lymph nodes)
Secondary outcomes: pathological stage, extent of tumour invasion
Notes Funding or conflicts of interest: No statement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated numbers
Allocation concealment (selection bias) High risk Unknown
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up and intention-to-treat
not described
Only one outcome
Limited details on inclusion and exclusion
43Laparoscopic versus open total mesorectal excision for rectal cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pechlivanides 2007 (Continued)
criteria
Selective reporting (reporting bias) Unclear risk No sample size calculation
Other bias High risk Significantly less anastomoses and more
ileostomies in the laparoscopic group
Surgeon’s experience: “most experienced
surgeon”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Surgical procedure described according to
TME
Postoperative protocol irrelevant for out-
come
Blinding of outcome assessment (detection
bias)
All outcomes




Number of patients assessed for eligibility but not randomised unknown
Inclusion period: June 2001 to September 2002
Participants n = 171 (LTME n = 82; OMTE n = 89)
Inclusion criteria: primary rectal cancer with lowest margin of tumour located under the
peritoneal reflection and 1.5 cm above the dentate line
Exclusion criteria: rectal cancer of other pathological type (e.g. lymphoma), emergency
surgery, Dukes D tumours with local infiltration affecting adjacent organs, participants
unwilling to take part in the study
Age (y): 45 vs 44 (mean)
Dukes stage (%): A 6 vs 7; B 12 vs 9; C 77 vs 76; D 5 vs 8
Tumour location: mid and low rectal cancer (lowest margin 1 - 8 cm)
Follow-up: range 1 - 16 months




(Neo)adjuvant therapy: not described
Outcomes Primary outcome: Feasibility and efficacy and short-term outcomes
Morbidity, mortality, duration of surgery, blood loss, analgesia requirement, time to
flatus, time to intake, time to defecation, pain score, hospital stay
Notes Funding or conflicts of interest: Funded by a National Outstanding Youth Foundation
of China grant
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Zhou 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The grouping was randomised
Allocation concealment (selection bias) High risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up and intention-to-treat
analysis unknown, conversion rate un-
known
Selective reporting (reporting bias) High risk No sample size calculation
Other bias Unclear risk Surgeons’ experience: 4 colorectal sur-
geons, experience unknown
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No standardised postoperative protocol de-
scribed
Blinding of outcome assessment (detection
bias)
All outcomes




Number of patients assessed for eligibility but not randomised unknown, but 4 excluded
after randomisation
Inclusion period: December 2004 to April 2007
Participants n = 71 (LTME n = 36; OTME n = 35)
Inclusion criteria: Histologically confirmed rectal cancer, suitable for elective surgery
Exclusion criteria:Neoadjuvant treatment,metastases, postoperative anastomotic leakage
Age (y): 56 vs 55 (mean)
Dukes stage (%): A 6 vs 6; B 47 vs 43; C 47 vs 51
Tumour location: rectal cancer > 5 cm
Follow-up: 5 days




Neoadjuvant therapy is exclusion criteria
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Zhou 2007 (Continued)
Outcomes Primary outcome not stated
Outcomes: Body temperature, WBC count, CRP level, Cortisol level, IL-6 level, VAS
score at -1, 1, 3 and 5 days
Notes Article translated from Chinese
Funding or conflicts of interest: Science and Research Fund of The Second Hospital of
Hebei Medical University
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random allocation
Allocation concealment (selection bias) Unclear risk Unknown
Incomplete outcome data (attrition bias)
All outcomes
High risk Conversion and intention-to-treat un-
known
Selective reporting (reporting bias) Unclear risk No sample size calculation
Other bias High risk Surgeon’s experience: unknown




Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective measurements
APR: abdominoperineal resection
AR: anterior resection




EORTC: European Organization for the Research and Treatment of Cancer
FAP: familial adenomatous polyposis
FSFI: Female sexual function index
HLA-DR: Human Leukocyte Antigen D related
HNPCC: hereditary non-polyposis colorectal cancer
HRQL: health-related quality of life
IIEF: Internation index of erectile function
I-PSS: International prostate symptom score
LAR: lower anterior resection
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MRI: magnetic resonance imaging
QLQ-CR38: Quality of life questionnaire - colorectal cancer-specific
TME: total mesorectal excision
VAS: visual analogue scale
WBC: white blood cells
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Braga 2002 Colorectal benign disease included, extended subgroup of rectal cancer participants described in Braga 2007
Braga 2005 Data on colorectal participants, extended subgroup of rectal cancer participants described in Braga 2007
JCOG 0404 2005 Colon cancer including rectosigmoid, rectal cancer excluded.
Kim 1998 Mid and low rectum excluded, number of upper rectum within proctosigmoid group unclear
LaFa 2011 Unknown number of rectal cancer participants included (anterior resection, left and right colectomy)
LAPKON II 2009 Colorectal participants, unknown number of rectal carcinoma > 12 cm included
Leung 1999 Only partially randomised and no intention-to-treat analysis
Liu 2009 No TME performed (D3 lymphadenectomy)
Milsom 1998 Benign disease included, no separate analysis on rectal cancer
Mirza 2008 Almost all participants were randomised within 2 other trials (MRC CLASICC a 2005; King 2006), not fully
randomised
Morris 2011 Comparison between CLASICC Trial data and national registry
Pan 2007 Surgeon in steep learning curve during study. Significant differences in outcome between early and late inclusion
groups. No numerical outcomes provided in abstract, no full-text available
Polle 2007 Benign disease and familial polyposis coli participants included
Schwenk 1998 Sphincter-preserving resection with TME is exclusion criterion
Stead 2000 Economic comparison between UK and USA trials
Yamamoto 2008 Non-randomised, single arm phase II trial
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Characteristics of ongoing studies [ordered by study ID]
ACTRN12609000663257
Trial name or title A La CaRT: Australasian Laparoscopic Cancer of the Rectum Trial A phase III prospective randomised trial
comparing laparoscopic-assisted resection versus open resection for rectal cancer
Methods Randomised controlled trial
Target sample size: 470
Participants Inclusion criteria: Histological diagnosis of adenocarcinoma of the rectum (<15cm from the anal verge as
measured by rigid sigmoidoscopy), T 1-3 N0 M0, T1-3 N1 M0 or T1-3 N0-1 M1 disease as determined
by pre-treatment CT scans and pelvic MRI or EUS. For patients with T3 or N1 disease, completion of pre-
operative 5FU-based chemotherapy and/or radiation therapy. Capecitabine may be substituted for 5FU, Age
>18 years, ECOG Performance Status: 0, 1 or 2, Written informed consent, Life expectancy of at least 12
weeks
Exclusion criteria: Medical or psychiatric conditions that compromise the patient’s ability to give informed
consent or comply with the study protocol. Pregnancy or breast feeding. Any uncontrolled concurrent medical
condition. Any co-morbid disease that would increase risk of morbidity. Participation in any investigational
drug study within the previous 4 weeks. Evidence of T4 disease extending to circumferential margin of
rectum or invading adjacent organs. Evidence of systemic disease (cardiovascular, renal, hepatic, etc.) that
would preclude surgery, or other severe incapacitating disease, ASA IV or ASA V. History of conditions that
would preclude use of a laparoscopic approach (e.g. multiple previous major laparotomies, severe adhesions)
. Concurrent or previous invasive pelvic malignancy (cervical, uterine and rectal) within five years prior to
registration
Interventions Laparoscopic-assisted resection versus open resection
Outcomes To determine whether laparoscopic-assisted resection is not inferior to open rectal resection as a safe, effec-
tive oncologic approach to rectal cancer and secondary from a patient related benefit perspective, based on
morbidity, mortality associated with surgery, disease-free survival and disease recurrence and quality of life
Starting date March 2010
Contact information Dr. Andrew Stevenson, c/o A La CaRT Trial Coordinator NHMRC Clinical Trials Centre Locked Bag 77,
Camperdown, 1450, Australia. alacart@ctc.usyd.edu.au
Notes Patient recruitment ongoing
NCT00726622
Trial name or title A phase III prospective randomized trial comparing laparoscopic-assisted resection versus open resection for
rectal cancer - ACOSOG Z6051
Methods Randomised controlled trial
Target sample size: 650
Follow-up 5 years
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NCT00726622 (Continued)
Participants Inclusion: Histologically confirmed adenocarcinoma of the rectum (<12 cm from the anal verge), T3, N0,
M0 or T1-3, N1-2, M0 disease by pre-neoadjuvant therapy CT scans and pelvic MRI or transrectal ul-
trasound. Completed neoadjuvant fluorouracil-based chemotherapy and/or radiotherapy within the past 4
weeks (Capecitabine may have been substituted for fluorouracil), ECOG performance status 0 - 2,
Exclusion: T4 disease, severe incapacitating disease (i.e., ASA IV or ASA V), systemic disease (e.g., cardio-
vascular, renal, or hepatic) that would preclude surgery, evidence of conditions (e.g., multiple prior major
laparotomies or severe adhesions) that would preclude use of a laparoscopic approach, pregnancy, Body mass
index > 34, other invasive pelvic malignancy (cervical, uterine, or rectal) within the past 5 years, history of
psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude
the patient from meeting the study requirements
Interventions Laparoscopic versus open rectal surgery
Outcomes Primary outcomes: Circumferential margin > 1 mm, Distal resected margin > 2 cm (or > 1 cm with clear
frozen section in the low rectum), Completeness of total mesorectal excision
Secondary outcomes: Patient-related benefit, disease-free survival (2 years), Local pelvic recurrence rates,
overall survival, quality of life, sexual function and bowel function
Starting date August 2008
Contact information James Fleshman, MD. American College of Surgeons Oncology Group. fleshman@wustl.edu
Notes Patient recruitment ongoing until Dec 2013
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D A T A A N D A N A L Y S E S
Comparison 1. Survival and recurrences




participants Statistical method Effect size
1 Disease-free survival 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 10-year 1 130 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.51, 3.06]
1.2 5-year 4 943 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.76, 1.38]
1.3 3-year 1 326 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.67, 1.74]
2 Overall survival 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 10-year 2 534 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.80, 1.65]
2.2 5-year 4 987 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.87, 1.52]
2.3 3-year 2 682 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.70, 1.42]
3 Local recurrences 8 1538 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.57, 1.39]
3.1 5-year 5 963 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.49, 1.81]
3.2 3-year 3 575 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.46, 1.56]
4 Distant recurrences 6 1341 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.70, 1.32]
5 Wound/port site metastases 7 2130 Odds Ratio (M-H, Fixed, 95% CI) 2.76 [0.75, 10.20]
Comparison 2. Surgical data




participants Statistical method Effect size
1 Lymph nodes retrieved 11 3682 Mean Difference (IV, Random, 95% CI) -0.43 [-1.13, 0.26]
2 CRM positivity 8 2313 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.71, 1.40]
3 Duration of surgery 12 3840 Mean Difference (IV, Random, 95% CI) 37.48 [27.80, 47.15]
4 Incision length 4 1488 Mean Difference (IV, Random, 95% CI) -12.83 [-14.87, -10.
80]
5 Conversion rate Other data No numeric data
6 Blood loss 8 2615 Mean Difference (IV, Random, 95% CI) -101.78 [-147.57, -
55.98]
7 Transfusion requirement 5 939 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.19, 0.62]
8 Intraoperative morbidity 4 1618 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.62, 1.18]
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Comparison 3. Short-term morbidity and mortality




participants Statistical method Effect size
1 30-day morbidity (total) 11 3397 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.80, 1.10]
2 Wound infection 10 3337 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.50, 0.93]
3 Bleeding 5 1181 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.10, 0.93]
4 Urinary complications 8 1756 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.83, 1.81]
5 Pneumonia 8 2668 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.83, 2.09]
6 Anastomotic leakage 10 2505 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.73, 1.40]
7 Need for reoperation 7 2316 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.57, 1.20]
8 30-day mortality 11 3812 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.50, 1.32]
Comparison 4. Postoperative recovery




participants Statistical method Effect size
1 Analgesia use (number of doses) 5 1199 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.93, -0.27]
2 Day 1 pain score (VAS) 3 776 Mean Difference (IV, Fixed, 95% CI) -0.74 [-1.04, -0.44]
3 Hospital stay (days) 11 3084 Mean Difference (IV, Random, 95% CI) -2.16 [-3.22, -1.10]
4 Time to normal diet (days) 8 2109 Mean Difference (IV, Random, 95% CI) -0.52 [-0.80, -0.23]
5 Time to first defecation (days) 8 2893 Mean Difference (IV, Random, 95% CI) -0.86 [-1.17, -0.54]
Comparison 5. Long term morbidity




participants Statistical method Effect size
1 Incisional hernia 3 508 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.32, 2.21]
2 Intestinal obstruction 3 508 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.12, 0.75]
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Analysis 1.1. Comparison 1 Survival and recurrences, Outcome 1 Disease-free survival.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 1 Survival and recurrences
Outcome: 1 Disease-free survival
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 10-year
Hong Kong b 2009 50/60 56/70 100.0 % 1.25 [ 0.51, 3.06 ]
Subtotal (95% CI) 60 70 100.0 % 1.25 [ 0.51, 3.06 ]
Total events: 50 (Laparoscopic), 56 (Open)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
2 5-year
Hong Kong a 2004 126/167 133/170 37.4 % 0.85 [ 0.52, 1.42 ]
Lujan 2009 86/101 84/103 14.3 % 1.30 [ 0.62, 2.72 ]
MRC CLASICC a 2005 115/217 57/109 41.2 % 1.03 [ 0.65, 1.63 ]
Ng 2008 31/40 26/36 7.1 % 1.32 [ 0.47, 3.75 ]
Subtotal (95% CI) 525 418 100.0 % 1.02 [ 0.76, 1.38 ]
Total events: 358 (Laparoscopic), 300 (Open)
Heterogeneity: Chi2 = 1.11, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
3 3-year
MRC CLASICC a 2005 141/217 69/109 100.0 % 1.08 [ 0.67, 1.74 ]
Subtotal (95% CI) 217 109 100.0 % 1.08 [ 0.67, 1.74 ]
Total events: 141 (Laparoscopic), 69 (Open)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 0.18, df = 2 (P = 0.91), I2 =0.0%
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Analysis 1.2. Comparison 1 Survival and recurrences, Outcome 2 Overall survival.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 1 Survival and recurrences
Outcome: 2 Overall survival
Study or subgroup Favours open Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 10-year
Hong Kong b 2009 49/76 42/77 27.1 % 1.51 [ 0.79, 2.90 ]
MRC CLASICC a 2005 49/128 96/253 72.9 % 1.01 [ 0.65, 1.57 ]
Subtotal (95% CI) 204 330 100.0 % 1.15 [ 0.80, 1.65 ]
Total events: 98 (Favours open), 138 (Open)
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
2 5-year
Hong Kong a 2004 127/167 124/170 31.8 % 1.18 [ 0.72, 1.92 ]
Lujan 2009 70/97 72/96 21.7 % 0.86 [ 0.46, 1.64 ]
MRC CLASICC a 2005 153/253 68/128 38.5 % 1.35 [ 0.88, 2.07 ]
Ng 2008 30/40 28/36 8.0 % 0.86 [ 0.30, 2.48 ]
Subtotal (95% CI) 557 430 100.0 % 1.15 [ 0.87, 1.52 ]
Total events: 380 (Favours open), 292 (Open)
Heterogeneity: Chi2 = 1.60, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
3 3-year
Liang 2011 127/167 142/172 54.8 % 0.67 [ 0.39, 1.14 ]
MRC CLASICC a 2005 165/230 73/113 45.2 % 1.39 [ 0.86, 2.25 ]
Subtotal (95% CI) 397 285 100.0 % 1.00 [ 0.70, 1.42 ]
Total events: 292 (Favours open), 215 (Open)
Heterogeneity: Chi2 = 3.99, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 1.3. Comparison 1 Survival and recurrences, Outcome 3 Local recurrences.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 1 Survival and recurrences
Outcome: 3 Local recurrences
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5-year
Hong Kong a 2004 11/167 7/170 16.1 % 1.64 [ 0.62, 4.34 ]
Liu 2010 0/98 0/88 Not estimable
Lujan 2009 5/97 5/96 11.8 % 0.99 [ 0.28, 3.53 ]
Ng 2008 2/40 4/36 9.9 % 0.42 [ 0.07, 2.45 ]
Zhou 2004 0/82 3/89 8.3 % 0.15 [ 0.01, 2.94 ]
Subtotal (95% CI) 484 479 46.0 % 0.94 [ 0.49, 1.81 ]
Total events: 18 (Laparoscopic), 19 (Open)
Heterogeneity: Chi2 = 3.52, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.17 (P = 0.86)
2 3-year
Araujo 2003 0/13 2/13 6.0 % 0.17 [ 0.01, 3.92 ]
Braga 2007 3/83 4/85 9.4 % 0.76 [ 0.16, 3.50 ]
MRC CLASICC a 2005 25/253 13/128 38.5 % 0.97 [ 0.48, 1.97 ]
Subtotal (95% CI) 349 226 54.0 % 0.84 [ 0.46, 1.56 ]
Total events: 28 (Laparoscopic), 19 (Open)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 833 705 100.0 % 0.89 [ 0.57, 1.39 ]
Total events: 46 (Laparoscopic), 38 (Open)
Heterogeneity: Chi2 = 4.78, df = 6 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 1.4. Comparison 1 Survival and recurrences, Outcome 4 Distant recurrences.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 1 Survival and recurrences
Outcome: 4 Distant recurrences
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 1/83 1/85 1.2 % 1.02 [ 0.06, 16.65 ]
Hong Kong a 2004 30/167 26/170 26.7 % 1.21 [ 0.68, 2.16 ]
Liu 2010 12/98 14/88 16.3 % 0.74 [ 0.32, 1.69 ]
Lujan 2009 11/97 15/96 16.9 % 0.69 [ 0.30, 1.59 ]
MRC CLASICC a 2005 47/253 21/128 28.7 % 1.16 [ 0.66, 2.05 ]
Ng 2008 6/40 9/36 10.2 % 0.53 [ 0.17, 1.67 ]
Total (95% CI) 738 603 100.0 % 0.96 [ 0.70, 1.32 ]
Total events: 107 (Laparoscopic), 86 (Open)
Heterogeneity: Chi2 = 3.09, df = 5 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Survival and recurrences, Outcome 5 Wound/port site metastases.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 1 Survival and recurrences
Outcome: 5 Wound/port site metastases
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hong Kong a 2004 0/167 0/170 Not estimable
Liang 2011 0/167 0/172 Not estimable
Liu 2010 0/98 0/88 Not estimable
Lujan 2009 0/103 0/101 Not estimable
MRC CLASICC a 2005 9/526 1/268 39.5 % 4.65 [ 0.59, 36.88 ]
Ng 2008 0/51 1/48 46.4 % 0.31 [ 0.01, 7.73 ]
Zhou 2004 2/82 0/89 14.1 % 5.56 [ 0.26, 117.53 ]
Total (95% CI) 1194 936 100.0 % 2.76 [ 0.75, 10.20 ]
Total events: 11 (Laparoscopic), 2 (Open)
Heterogeneity: Chi2 = 2.22, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Surgical data, Outcome 1 Lymph nodes retrieved.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 2 Surgical data
Outcome: 1 Lymph nodes retrieved





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Araujo 2003 13 5.5 (0) 15 11.9 (0) Not estimable
Braga 2007 83 12.7 (7.3) 85 13.6 (6.9) 7.1 % -0.90 [ -3.05, 1.25 ]
COLOR 2 a 2013 699 13 (5.9) 345 14 (6.7) 16.7 % -1.00 [ -1.83, -0.17 ]
Hong Kong a 2004 203 11.1 (7.9) 200 12.1 (7.1) 11.1 % -1.00 [ -2.47, 0.47 ]
Kang 2010 170 17 (7.4) 170 18 (8.1) 9.8 % -1.00 [ -2.65, 0.65 ]
Liang 2011 169 7.05 (5.05) 174 7.44 (4.89) 14.6 % -0.39 [ -1.44, 0.66 ]
Liu 2010 98 16 (4.4) 88 15 (7.4) 9.0 % 1.00 [ -0.77, 2.77 ]
Lujan 2009 101 13.63 (6.26) 103 11.57 (5.1) 10.3 % 2.06 [ 0.49, 3.63 ]
MRC CLASICC a 2005 526 12 (6.7) 268 13.5 (8.1) 13.9 % -1.50 [ -2.63, -0.37 ]
Ng 2008 51 12.4 (6.7) 48 13 (7) 5.1 % -0.60 [ -3.30, 2.10 ]
Pechlivanides 2007 34 19.2 (8.3) 39 19.2 (10) 2.4 % 0.0 [ -4.20, 4.20 ]
Total (95% CI) 2147 1535 100.0 % -0.43 [ -1.13, 0.26 ]
Heterogeneity: Tau2 = 0.57; Chi2 = 18.32, df = 9 (P = 0.03); I2 =51%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Surgical data, Outcome 2 CRM positivity.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 2 Surgical data
Outcome: 2 CRM positivity
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 1/83 2/85 2.9 % 0.51 [ 0.05, 5.69 ]
COLOR 2 a 2013 56/588 30/300 54.3 % 0.95 [ 0.59, 1.51 ]
Hong Kong b 2009 2/76 1/77 1.5 % 2.05 [ 0.18, 23.14 ]
Kang 2010 5/170 7/170 10.3 % 0.71 [ 0.22, 2.27 ]
Lujan 2009 4/101 3/103 4.3 % 1.37 [ 0.30, 6.30 ]
MRC CLASICC a 2005 30/193 14/97 23.8 % 1.09 [ 0.55, 2.17 ]
Ng 2008 3/51 2/48 2.9 % 1.44 [ 0.23, 9.00 ]
Zhou 2004 0/82 0/89 Not estimable
Total (95% CI) 1344 969 100.0 % 0.99 [ 0.71, 1.40 ]
Total events: 101 (Laparoscopic), 59 (Open)
Heterogeneity: Chi2 = 1.42, df = 6 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Surgical data, Outcome 3 Duration of surgery.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 2 Surgical data
Outcome: 3 Duration of surgery





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Araujo 2003 13 228 (0) 15 284 (0) Not estimable
Braga 2007 83 262 (72) 85 209 (70) 7.5 % 53.00 [ 31.52, 74.48 ]
COLOR 2 a 2013 699 240 (116) 345 188 (90) 9.9 % 52.00 [ 39.19, 64.81 ]
Hong Kong a 2004 203 189.9 (55.4) 200 144.2 (57.8) 10.4 % 45.70 [ 34.64, 56.76 ]
Kang 2010 170 244.9 (75.4) 170 197 (62.9) 9.4 % 47.90 [ 33.14, 62.66 ]
King 2006 41 187 (65) 19 140 (50) 5.6 % 47.00 [ 16.98, 77.02 ]
Liang 2011 169 138.08 (23.79) 174 118.53 (21.989) 11.6 % 19.55 [ 14.70, 24.40 ]
Liu 2010 98 161 (35) 88 140 (20) 11.0 % 21.00 [ 12.91, 29.09 ]
Lujan 2009 101 193.7 (45.1) 103 172.9 (59.4) 9.4 % 20.80 [ 6.34, 35.26 ]
MRC CLASICC a 2005 526 180 (63) 268 135 (60) 10.9 % 45.00 [ 36.02, 53.98 ]
Ng 2008 51 213.5 (46.2) 48 163.7 (43.4) 8.6 % 49.80 [ 32.15, 67.45 ]
Zhou 2004 82 120 (81) 89 106 (111) 5.8 % 14.00 [ -14.97, 42.97 ]
Total (95% CI) 2236 1604 100.0 % 37.48 [ 27.80, 47.15 ]
Heterogeneity: Tau2 = 203.59; Chi2 = 71.21, df = 10 (P<0.00001); I2 =86%
Test for overall effect: Z = 7.59 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Surgical data, Outcome 4 Incision length.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 2 Surgical data
Outcome: 4 Incision length





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Braga 2007 83 5.8 (0.8) 85 19.1 (3.1) 25.2 % -13.30 [ -13.98, -12.62 ]
Kang 2010 170 5 (1.1) 170 20 (3.7) 25.4 % -15.00 [ -15.58, -14.42 ]
Liu 2010 98 6 (1) 88 17 (2) 25.6 % -11.00 [ -11.46, -10.54 ]
MRC CLASICC a 2005 526 10 (8.1) 268 22 (8.1) 23.8 % -12.00 [ -13.19, -10.81 ]
Total (95% CI) 877 611 100.0 % -12.83 [ -14.87, -10.80 ]
Heterogeneity: Tau2 = 4.17; Chi2 = 116.55, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 12.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Surgical data, Outcome 5 Conversion rate.
Conversion rate
Study
Araujo 2003 0 (0/13)
Braga 2007 7.2 (6/83)
COLOR 2 a 2013 17 (121/695)
Hong Kong a 2004 23.2 (47/203)
Kang 2010 1.2 (2/170)
King 2006 7.3 (3/41)
Liang 2011 0.5 (1/169)
Liu 2010 0 (0/98)
Lujan 2009 7.9 (8/101)
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Conversion rate (Continued)
MRC CLASICC a 2005 33.9 (82/242)
Ng 2008 9.8 (5/51)
Pechlivanides 2007 2.9 (1/34)
Zhou 2004 Unknown
Zhou 2007 Unknown
Analysis 2.6. Comparison 2 Surgical data, Outcome 6 Blood loss.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 2 Surgical data
Outcome: 6 Blood loss





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Braga 2007 83 213 (236) 85 396 (367) 10.4 % -183.00 [ -276.09, -89.91 ]
COLOR 2 a 2013 699 200 (222) 345 400 (370) 15.8 % -200.00 [ -242.37, -157.63 ]
Hong Kong a 2004 203 169 (500) 200 238 (972) 6.1 % -69.00 [ -220.25, 82.25 ]
Kang 2010 170 200 (148) 170 217.5 (185) 16.4 % -17.50 [ -53.11, 18.11 ]
Liu 2010 98 310 (96) 88 380 (85) 17.2 % -70.00 [ -96.01, -43.99 ]
Lujan 2009 101 127.8 (113.3) 103 234.2 (174.3) 16.0 % -106.40 [ -146.67, -66.13 ]
Ng 2008 51 321.7 (750) 48 555.6 (1180) 1.3 % -233.90 [ -626.08, 158.28 ]
Zhou 2004 82 20 (85) 89 92 (111) 16.9 % -72.00 [ -101.50, -42.50 ]
Total (95% CI) 1487 1128 100.0 % -101.78 [ -147.57, -55.98 ]
Heterogeneity: Tau2 = 2998.32; Chi2 = 50.06, df = 7 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.36 (P = 0.000013)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Surgical data, Outcome 7 Transfusion requirement.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 2 Surgical data
Outcome: 7 Transfusion requirement
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Araujo 2003 3/13 10/15 18.4 % 0.15 [ 0.03, 0.80 ]
Braga 2007 6/83 22/85 51.9 % 0.22 [ 0.09, 0.58 ]
Kang 2010 0/170 1/170 3.9 % 0.33 [ 0.01, 8.19 ]
King 2006 6/41 2/19 6.0 % 1.46 [ 0.27, 7.99 ]
Liang 2011 4/169 8/174 19.8 % 0.50 [ 0.15, 1.70 ]
Total (95% CI) 476 463 100.0 % 0.34 [ 0.19, 0.62 ]
Total events: 19 (Laparoscopic), 43 (Open)
Heterogeneity: Chi2 = 4.85, df = 4 (P = 0.30); I2 =18%
Test for overall effect: Z = 3.52 (P = 0.00043)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Surgical data, Outcome 8 Intraoperative morbidity.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 2 Surgical data
Outcome: 8 Intraoperative morbidity
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Araujo 2003 2/13 4/15 4.0 % 0.50 [ 0.08, 3.32 ]
COLOR 2 a 2013 81/694 49/344 73.0 % 0.80 [ 0.54, 1.16 ]
MRC CLASICC a 2005 35/253 16/128 23.1 % 1.12 [ 0.60, 2.12 ]
Zhou 2004 0/82 0/89 Not estimable
Total (95% CI) 1042 576 100.0 % 0.86 [ 0.62, 1.18 ]
Total events: 118 (Laparoscopic), 69 (Open)
Heterogeneity: Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Short-term morbidity and mortality, Outcome 1 30-day morbidity (total).
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 3 Short-term morbidity and mortality
Outcome: 1 30-day morbidity (total)
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 24/83 34/85 7.7 % 0.61 [ 0.32, 1.16 ]
COLOR 2 a 2013 278/697 128/345 33.0 % 1.12 [ 0.86, 1.47 ]
Hong Kong a 2004 40/203 45/200 11.7 % 0.85 [ 0.52, 1.37 ]
Kang 2010 36/170 40/170 10.1 % 0.87 [ 0.52, 1.46 ]
King 2006 6/41 5/19 1.9 % 0.48 [ 0.13, 1.83 ]
Liang 2011 19/169 21/174 5.9 % 0.92 [ 0.48, 1.79 ]
Liu 2010 5/98 9/88 2.9 % 0.47 [ 0.15, 1.47 ]
Lujan 2009 34/101 34/103 7.2 % 1.03 [ 0.58, 1.84 ]
MRC CLASICC a 2005 101/253 47/128 12.0 % 1.15 [ 0.74, 1.78 ]
Ng 2008 23/51 25/48 4.5 % 0.76 [ 0.34, 1.67 ]
Zhou 2004 5/82 11/89 3.2 % 0.46 [ 0.15, 1.39 ]
Total (95% CI) 1948 1449 100.0 % 0.94 [ 0.80, 1.10 ]
Total events: 571 (Laparoscopic), 399 (Open)
Heterogeneity: Chi2 = 8.92, df = 10 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Short-term morbidity and mortality, Outcome 2 Wound infection.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 3 Short-term morbidity and mortality
Outcome: 2 Wound infection
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 6/83 13/85 12.2 % 0.43 [ 0.16, 1.20 ]
COLOR 2 a 2013 28/697 17/345 22.3 % 0.81 [ 0.44, 1.50 ]
Hong Kong a 2004 9/203 15/200 14.8 % 0.57 [ 0.24, 1.34 ]
Kang 2010 2/170 11/170 11.1 % 0.17 [ 0.04, 0.79 ]
Liang 2011 9/169 8/174 7.6 % 1.17 [ 0.44, 3.10 ]
Liu 2010 3/98 4/88 4.2 % 0.66 [ 0.14, 3.05 ]
Lujan 2009 0/101 2/103 2.5 % 0.20 [ 0.01, 4.22 ]
MRC CLASICC a 2005 33/253 15/128 17.7 % 1.13 [ 0.59, 2.17 ]
Ng 2008 0/51 4/48 4.7 % 0.10 [ 0.01, 1.83 ]
Zhou 2004 2/82 3/89 2.9 % 0.72 [ 0.12, 4.40 ]
Total (95% CI) 1907 1430 100.0 % 0.68 [ 0.50, 0.93 ]
Total events: 92 (Laparoscopic), 92 (Open)
Heterogeneity: Chi2 = 10.16, df = 9 (P = 0.34); I2 =11%
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Short-term morbidity and mortality, Outcome 3 Bleeding.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 3 Short-term morbidity and mortality
Outcome: 3 Bleeding
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 0/83 4/85 34.2 % 0.11 [ 0.01, 2.05 ]
Hong Kong a 2004 2/203 4/200 30.9 % 0.49 [ 0.09, 2.69 ]
Kang 2010 1/170 3/170 23.1 % 0.33 [ 0.03, 3.20 ]
Ng 2008 0/51 1/48 11.8 % 0.31 [ 0.01, 7.73 ]
Zhou 2004 0/82 0/89 Not estimable
Total (95% CI) 589 592 100.0 % 0.30 [ 0.10, 0.93 ]
Total events: 3 (Laparoscopic), 12 (Open)
Heterogeneity: Chi2 = 0.78, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.036)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Short-term morbidity and mortality, Outcome 4 Urinary complications.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 3 Short-term morbidity and mortality
Outcome: 4 Urinary complications
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Araujo 2003 1/13 1/15 1.8 % 1.17 [ 0.07, 20.72 ]
Braga 2007 2/83 5/85 10.4 % 0.40 [ 0.07, 2.10 ]
Hong Kong a 2004 13/203 10/200 20.3 % 1.30 [ 0.56, 3.04 ]
Kang 2010 17/170 7/170 13.6 % 2.59 [ 1.04, 6.41 ]
Liang 2011 1/169 1/174 2.1 % 1.03 [ 0.06, 16.60 ]
Lujan 2009 13/101 10/103 18.6 % 1.37 [ 0.57, 3.29 ]
Ng 2008 17/51 17/48 25.1 % 0.91 [ 0.40, 2.09 ]
Zhou 2004 2/82 4/89 8.1 % 0.53 [ 0.09, 2.98 ]
Total (95% CI) 872 884 100.0 % 1.23 [ 0.83, 1.81 ]
Total events: 66 (Laparoscopic), 55 (Open)
Heterogeneity: Chi2 = 5.86, df = 7 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Short-term morbidity and mortality, Outcome 5 Pneumonia.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 3 Short-term morbidity and mortality
Outcome: 5 Pneumonia
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Araujo 2003 1/13 0/15 1.3 % 3.72 [ 0.14, 99.48 ]
Braga 2007 3/83 2/85 5.9 % 1.56 [ 0.25, 9.56 ]
COLOR 2 a 2013 20/697 10/345 40.5 % 0.99 [ 0.46, 2.14 ]
Hong Kong a 2004 4/203 3/200 9.2 % 1.32 [ 0.29, 5.97 ]
Liang 2011 2/169 2/174 6.1 % 1.03 [ 0.14, 7.40 ]
Lujan 2009 1/101 4/103 12.2 % 0.25 [ 0.03, 2.25 ]
MRC CLASICC a 2005 25/253 5/128 18.6 % 2.70 [ 1.01, 7.22 ]
Ng 2008 2/51 2/48 6.2 % 0.94 [ 0.13, 6.94 ]
Total (95% CI) 1570 1098 100.0 % 1.32 [ 0.83, 2.09 ]
Total events: 58 (Laparoscopic), 28 (Open)
Heterogeneity: Chi2 = 5.35, df = 7 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Short-term morbidity and mortality, Outcome 6 Anastomotic leakage.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 3 Short-term morbidity and mortality
Outcome: 6 Anastomotic leakage
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 8/76 9/74 11.2 % 0.85 [ 0.31, 2.34 ]
COLOR 2 a 2013 58/461 25/240 39.5 % 1.24 [ 0.75, 2.04 ]
Hong Kong a 2004 1/203 4/200 5.5 % 0.24 [ 0.03, 2.19 ]
Kang 2010 2/151 0/146 0.7 % 4.90 [ 0.23, 102.93 ]
King 2006 1/12 0/4 0.9 % 1.17 [ 0.04, 34.52 ]
Liang 2011 4/86 6/104 7.1 % 0.80 [ 0.22, 2.92 ]
Liu 2010 2/72 3/63 4.3 % 0.57 [ 0.09, 3.53 ]
Lujan 2009 5/77 10/81 12.5 % 0.49 [ 0.16, 1.51 ]
MRC CLASICC a 2005 26/190 9/94 14.3 % 1.50 [ 0.67, 3.34 ]
Zhou 2004 1/82 3/89 3.9 % 0.35 [ 0.04, 3.47 ]
Total (95% CI) 1410 1095 100.0 % 1.01 [ 0.73, 1.40 ]
Total events: 108 (Laparoscopic), 69 (Open)
Heterogeneity: Chi2 = 7.22, df = 9 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Short-term morbidity and mortality, Outcome 7 Need for reoperation.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 3 Short-term morbidity and mortality
Outcome: 7 Need for reoperation
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 6/83 11/85 16.8 % 0.52 [ 0.18, 1.49 ]
COLOR 2 a 2013 42/697 20/345 41.8 % 1.04 [ 0.60, 1.80 ]
Hong Kong a 2004 6/203 5/200 8.1 % 1.19 [ 0.36, 3.96 ]
Kang 2010 3/170 3/170 4.9 % 1.00 [ 0.20, 5.03 ]
King 2006 2/41 3/19 6.5 % 0.27 [ 0.04, 1.79 ]
Lujan 2009 8/101 10/103 15.2 % 0.80 [ 0.30, 2.12 ]
Ng 2008 1/51 4/48 6.7 % 0.22 [ 0.02, 2.04 ]
Total (95% CI) 1346 970 100.0 % 0.82 [ 0.57, 1.20 ]
Total events: 68 (Laparoscopic), 56 (Open)
Heterogeneity: Chi2 = 4.51, df = 6 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Short-term morbidity and mortality, Outcome 8 30-day mortality.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 3 Short-term morbidity and mortality
Outcome: 8 30-day mortality
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 1/83 1/85 2.8 % 1.02 [ 0.06, 16.65 ]
COLOR 2 a 2013 8/699 6/345 22.9 % 0.65 [ 0.23, 1.90 ]
Hong Kong a 2004 5/203 4/200 11.3 % 1.24 [ 0.33, 4.68 ]
Kang 2010 0/170 0/170 Not estimable
King 2006 1/41 1/19 3.8 % 0.45 [ 0.03, 7.60 ]
Liang 2011 0/169 0/174 Not estimable
Liu 2010 0/98 0/88 Not estimable
Lujan 2009 2/101 3/103 8.4 % 0.67 [ 0.11, 4.12 ]
MRC CLASICC a 2005 21/526 13/268 47.7 % 0.82 [ 0.40, 1.66 ]
Ng 2008 1/51 1/48 2.9 % 0.94 [ 0.06, 15.46 ]
Zhou 2004 0/82 0/89 Not estimable
Total (95% CI) 2223 1589 100.0 % 0.81 [ 0.50, 1.32 ]
Total events: 39 (Laparoscopic), 29 (Open)
Heterogeneity: Chi2 = 0.79, df = 6 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Postoperative recovery, Outcome 1 Analgesia use (number of doses).
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 4 Postoperative recovery
Outcome: 1 Analgesia use (number of doses)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hong Kong a 2004 203 4.5 (3.8) 200 6.9 (8.2) 21.8 % -0.38 [ -0.57, -0.18 ]
Kang 2010 170 107 (52) 170 157 (50.5) 21.3 % -0.97 [ -1.20, -0.75 ]
Liu 2010 98 2 (1) 88 3 (1) 19.6 % -1.00 [ -1.30, -0.69 ]
Ng 2008 51 6 (11.8) 48 11.4 (12.3) 17.5 % -0.44 [ -0.84, -0.05 ]
Zhou 2004 82 3.9 (0.9) 89 4.1 (1.1) 19.7 % -0.20 [ -0.50, 0.10 ]
Total (95% CI) 604 595 100.0 % -0.60 [ -0.93, -0.27 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 29.47, df = 4 (P<0.00001); I2 =86%
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Postoperative recovery, Outcome 2 Day 1 pain score (VAS).
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 4 Postoperative recovery
Outcome: 2 Day 1 pain score (VAS)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hong Kong a 2004 167 4.6 (2.4) 170 5.4 (2.3) 35.7 % -0.80 [ -1.30, -0.30 ]
Kang 2010 170 4.7 (2) 170 5.5 (2) 49.8 % -0.80 [ -1.23, -0.37 ]
Ng 2008 51 4.5 (2.1) 48 4.9 (1.9) 14.5 % -0.40 [ -1.19, 0.39 ]
Total (95% CI) 388 388 100.0 % -0.74 [ -1.04, -0.44 ]
Heterogeneity: Chi2 = 0.85, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Postoperative recovery, Outcome 3 Hospital stay (days).
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 4 Postoperative recovery
Outcome: 3 Hospital stay (days)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Araujo 2003 13 10.5 (0) 15 0 (0) Not estimable
Braga 2007 83 10 (4.9) 85 13.6 (10) 7.9 % -3.60 [ -5.97, -1.23 ]
COLOR 2 a 2013 699 8 (7) 345 9 (5.2) 12.3 % -1.00 [ -1.76, -0.24 ]
Hong Kong a 2004 203 8.2 (16.2) 200 8.7 (6) 7.9 % -0.50 [ -2.88, 1.88 ]
Kang 2010 170 8 (3.7) 170 9 (3) 12.4 % -1.00 [ -1.72, -0.28 ]
King 2006 41 5.2 (4.2) 19 7.4 (3.9) 8.4 % -2.20 [ -4.37, -0.03 ]
Liu 2010 98 12 (2) 88 15 (3) 12.3 % -3.00 [ -3.74, -2.26 ]
Lujan 2009 101 8.2 (7.3) 103 9.9 (6.8) 9.1 % -1.70 [ -3.64, 0.24 ]
MRC CLASICC a 2005 253 11 (4.4) 128 13 (6.7) 11.0 % -2.00 [ -3.28, -0.72 ]
Ng 2008 51 10.8 (5.5) 48 11.5 (8.3) 6.9 % -0.70 [ -3.49, 2.09 ]
Zhou 2004 82 8.1 (3.1) 89 13.3 (3.4) 11.8 % -5.20 [ -6.17, -4.23 ]
Total (95% CI) 1794 1290 100.0 % -2.16 [ -3.22, -1.10 ]
Heterogeneity: Tau2 = 2.22; Chi2 = 66.09, df = 9 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.01 (P = 0.000062)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Postoperative recovery, Outcome 4 Time to normal diet (days).
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 4 Postoperative recovery
Outcome: 4 Time to normal diet (days)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Braga 2007 83 3.7 (1.3) 85 5 (2) 13.0 % -1.30 [ -1.81, -0.79 ]
Hong Kong a 2004 203 4.2 (3) 200 4.9 (2.2) 12.9 % -0.70 [ -1.21, -0.19 ]
Kang 2010 170 3.5 (0.9) 170 3.8 (1.1) 20.0 % -0.30 [ -0.51, -0.09 ]
Liang 2011 169 5.71 (1.716) 174 6.34 (1.618) 16.7 % -0.63 [ -0.98, -0.28 ]
Lujan 2009 101 2.8 (4.4) 103 3.6 (3.4) 5.2 % -0.80 [ -1.88, 0.28 ]
MRC CLASICC a 2005 253 6 (2.2) 128 6 (2.2) 13.9 % 0.0 [ -0.47, 0.47 ]
Ng 2008 51 4.3 (5.8) 48 5.1 (3.3) 2.1 % -0.80 [ -2.65, 1.05 ]
Zhou 2004 82 4.3 (1.1) 89 4.5 (1.4) 16.1 % -0.20 [ -0.58, 0.18 ]
Total (95% CI) 1112 997 100.0 % -0.52 [ -0.80, -0.23 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 20.23, df = 7 (P = 0.01); I2 =65%
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Postoperative recovery, Outcome 5 Time to first defecation (days).
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 4 Postoperative recovery
Outcome: 5 Time to first defecation (days)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
COLOR 2 a 2013 666 2 (1.5) 337 3 (1.5) 16.2 % -1.00 [ -1.20, -0.80 ]
Hong Kong a 2004 203 4 (2) 200 4.6 (2.5) 12.9 % -0.60 [ -1.04, -0.16 ]
Hong Kong b 2009 76 4.1 (1.5) 77 4.7 (1.8) 11.7 % -0.60 [ -1.12, -0.08 ]
Kang 2010 170 4 (1.7) 170 5.1 (1.9) 13.8 % -1.10 [ -1.48, -0.72 ]
Liang 2011 169 3.9 (0.85) 174 4.2 (0.79) 16.5 % -0.30 [ -0.47, -0.13 ]
MRC CLASICC a 2005 253 5 (2.2) 128 6 (2.2) 12.6 % -1.00 [ -1.47, -0.53 ]
Ng 2008 51 4.3 (5.3) 48 6.3 (2.8) 3.0 % -2.00 [ -3.66, -0.34 ]
Zhou 2004 82 1.5 (1.3) 89 2.7 (1.5) 13.3 % -1.20 [ -1.62, -0.78 ]
Total (95% CI) 1670 1223 100.0 % -0.86 [ -1.17, -0.54 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 43.17, df = 7 (P<0.00001); I2 =84%
Test for overall effect: Z = 5.31 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Long term morbidity, Outcome 1 Incisional hernia.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 5 Long term morbidity
Outcome: 1 Incisional hernia








Braga 2007 0/83 4/85 10.1 % 0.11 [ 0.01, 2.05 ]
Hong Kong b 2009 4/76 5/77 37.8 % 0.80 [ 0.21, 3.10 ]
MRC CLASICC a 2005 14/129 5/58 52.1 % 1.29 [ 0.44, 3.77 ]
Total (95% CI) 288 220 100.0 % 0.84 [ 0.32, 2.21 ]
Total events: 18 (Laparoscopic), 14 (Open)
Heterogeneity: Tau2 = 0.17; Chi2 = 2.55, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laparoscopic Favours open
Analysis 5.2. Comparison 5 Long term morbidity, Outcome 2 Intestinal obstruction.
Review: Laparoscopic versus open total mesorectal excision for rectal cancer
Comparison: 5 Long term morbidity
Outcome: 2 Intestinal obstruction
Study or subgroup Laparoscopic Open Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Braga 2007 0/83 1/85 8.5 % 0.34 [ 0.01, 8.40 ]
Hong Kong b 2009 2/76 15/77 83.8 % 0.11 [ 0.02, 0.51 ]
MRC CLASICC a 2005 5/129 1/58 7.7 % 2.30 [ 0.26, 20.13 ]
Total (95% CI) 288 220 100.0 % 0.30 [ 0.12, 0.75 ]
Total events: 7 (Laparoscopic), 17 (Open)
Heterogeneity: Chi2 = 5.03, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 2.56 (P = 0.011)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours laparoscopic Favours open
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A D D I T I O N A L T A B L E S








































28 - - + - + - - + + - - -
Braga
2007
























40 - - - - - - - - - + - -
Kang
2010
340 - + + - + + + + + - + -
King
2006
19 - + + - - - - + + - + +
Liang
2011
343 3y + + - + + - + - - - -
Liu
2010
186 - + + - + - - + + - - -
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Table 1. Reported outcomes (Continued)
Lujan
2009

















236 - - - - - - - - - + - -
Ng
2008




73 - - - - + - - - - - - -
Zhou
2004
171 - + + - - + - + + - - -
Zhou
2007
71 - - - - - - - - - + - -
A P P E N D I C E S
Appendix 1. Cochrane Library (CENTRAL) search strategy
# Search
1 MeSH descriptor: [Laparoscopy] explode all trees
2 MeSH descriptor: [Surgical Procedures, Minimally Invasive] explode all trees
3 laparoscopy OR laparoscop* OR minimally invasive surgery
79Laparoscopic versus open total mesorectal excision for rectal cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
4 (#1 or #2 or #3)
5 (anterior resecti*) OR (abdominoperineal resecti*) OR (total mesorectal excisi*)
6 ((sexual* or gastrointestinal or urogenital or bladder) near/3 functi*):ti,ab,kw
7 (quality of life or QoL or survival or recurrence):ti,ab,kw
8 MeSH descriptor: [Erectile Dysfunction] explode all trees
9 MeSH descriptor: [Urinary Bladder] explode all trees
10 MeSH descriptor: [Quality of Life] explode all trees
11 MeSH descriptor: [Survival] explode all trees
12 MeSH descriptor: [Recurrence] explode all trees
13 (#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12)
14 MeSH descriptor: [Rectal Neoplasms] explode all trees
15 ((rect* or anal* or anus*) near/3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom*)):ti,
ab,kw
16 (#14 or #15)
17 (#4 and #13 and #16)
Appendix 2. MEDLINE (Ovid) search strategy
# Search
1 exp Laparoscopy/
2 exp Surgical Procedures, Minimally Invasive/
3 (laparoscop* or minimally invasive surgery).mp.
4 1 or 2 or 3
5 (anterior resecti* or abdominoperineal resecti* or total mesorectal excisi*).mp
6 ((sexual* or gastrointestinal or urogenital or bladder) adj3 functi*).mp
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(Continued)
7 (quality of life or QoL or survival or recurrence).mp.
8 exp sexual dysfunction, physiological/ or exp urinary bladder/ or exp quality of life/ or exp survival/ or exp recurrence/
9 5 or 6 or 7 or 8
10 exp Rectal Neoplasms/
11 ((rect* or anal* or anus*) adj3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom*)).mp
12 10 or 11
13 4 and 9 and 12
14 randomized controlled trial.pt.






21 14 or 15 or 16 or 17 or 18 or 19 or 20
22 humans.sh.
23 21 and 22
24 13 and 23
25 limit 24 to yr=“1990 -Current”
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Appendix 3. EMBASE (Ovid) search strategy
# Search
1 exp LAPAROSCOPY/
2 exp minimally invasive surgery/
3 (laparoscop* or minimally invasive surgery).mp.
4 1 or 2 or 3
5 exp rectum anterior resection/ or exp rectum abdominoperineal resection/ or exp sexual function/ or exp bladder/ or exp quality
of life/ or exp survival/ or exp recurrent disease/
6 (anterior resecti* or abdominoperineal resecti* or total mesorectal excisi* or quality of life or QoL or survival or recurrence).mp
7 ((sexual* or gastrointestinal or urogenital or bladder) adj3 functi*).mp
8 5 or 6 or 7
9 exp rectum tumor/
10 ((rect* or anal* or anus*) adj3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom*)).mp
11 9 or 10
12 4 and 8 and 11




17 phase 3 clinical trial/
18 phase 4 clinical trial/
19 double blind procedure/
20 single blind procedure/
21 ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).ti,ab
22 (random* or cross* over* or factorial* or placebo* or volunteer*).ti,ab
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(Continued)
23 18 or 15 or 19 or 21 or 14 or 20 or 16 or 13 or 22 or 17
24 “human*”.ti,ab.
25 (animal* or nonhuman*).ti,ab.
26 25 and 24
27 25 not 26
28 23 not 27
29 12 and 28
30 limit 29 to yr=“1990 -Current”
WH A T ’ S N E W
Last assessed as up-to-date: 2 February 2013.
Date Event Description
2 February 2013 New citation required and conclusions have changed New search, analysis and conclusion
2 February 2013 New search has been performed In this updated review we included 14 trials (20 compar-
isons) ; 46 previously included studies from the first pub-
lished version in 2006 were discarded and 12 new RCTs
added
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 4, 2006
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Date Event Description
5 August 2008 Amended Converted to new review format.
10 August 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Sandra Vennix, MD: First reviewer to search literature, assess quality of trials and collect data, manage the data and write the review.
Loeki Pelzers, MD: Second reviewer to search literature, assess quality of trials and collect data.
Nicole Bouvy, MD, PhD: Providing general advice on the review, help write the review.
Geerard Beets, MD, PhD: Providing general advice on the review, help write the review.
Jean-Pierre Pierie, MD, PhD: Performing previous work that was the foundation of the current review, providing general advice on the
review.
Theo Wiggers, MD, PhD: Performing previous work that was the foundation of the current review, providing general advice on the
review.
Stephanie Breukink,MD, PhD:Writing the protocol, performing previouswork that was the foundation of the current review, providing
general advice on the review, co-ordinating the review.
D E C L A R A T I O N S O F I N T E R E S T
No funding/conflicts of interest declared by all authors.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since the published protocol and original review, in this version we only include randomised controlled trials (RCTs) which compared
laparoscopic with open total mesorectal excision. This has resulted in discarding the 46 non-randomised studies of the 48 included
studies in favour of 12 new RCTs not originally included.In addition to the outcome measures given in the protocol, we have included
long-term morbidity, recurrences and overall survival. We have excluded the respiratory recovery rate, as the definition is unclear and
only one trial reported on this outcome.
For methodological assessment, we have discarded the scale by Sackett 2000, because we now only include randomised controlled trials.
We now assess the included trials according to the CONSORT Statement 2010 and using the Cochrane ’Risk of bias’ tool.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Laparoscopy; Conversion to Open Surgery [statistics & numerical data]; Elective Surgical Procedures; Rectal Neoplasms [∗surgery];
Rectum [∗surgery]; Treatment Outcome
MeSH check words
Humans
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